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Abstract 
 
 Stem cell differentiation into endothelial cells has been an active field of research within 
the last years. The increased interest in this research field is a consequence of the huge clinical 
relevance of these cells and the associated future regenerative medicine treatments that could 
improve the recovery of pos-ischemic conditions and other angiogenic related states. 
 Despite this increase in research, nowadays the differentiation strategies into the 
endothelial lineage are very inefficient. This inefficiency is related both to the lack of 
information regarding the ideal cell source to the differentiation process and to the non-
standardization of the in vitro conditions to induce the endothelial lineage commitment (growth 
factors, matrices, cytokines). Therefore strategies that permit a real time monitorization of the 
differentiation process, like viral transduction of tagged DNA, is a reliable and efficient way to 
evaluate these kinds of processes.  
 In this context, the main aim of this project was to generate a lentiviral tool specific for 
detecting the expression of an endothelial late marker (vascular endothelial-cadherin – VE-
cadherin).  
This objective was accomplished through the ligation of the VE-cadherin promoter and a 
mCherry fluorescent tag.  After generating the reporter system, the validation of this tool was 
done by infecting human umbilical vein endothelial cells (HUVECs) and induced pluripotent 
stem cells (iPSCs). The results show that 5 days after infection HUVECs present an increased 
pattern of red fluorescence and no alteration was observed within the infected iPSCs. There is 
already on-going work to differentiate the infected iPSCs and monitor the red fluorescence 
levels. 
 Additionally, some information was generated regarding the internalization of organic 
nanoparticles (NPs) and adhesion and proliferation of iPSCs in possible endothelial inductive 
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substrates. The results show that the iPSCs are able to internalize nanoparticles even when the 
NPs are adhered to the substrate.  
 In conclusion, the results show the successful creation of a lentiviral construct that 
permits the direct monitorization of expression of mCherry associated with VE-cadherin 
promoter. In the future this might be a powerful tool either to be used in a stem cell context or to 
explore other cell sources and processes like transdifferentiation. 
 
 
Keywords: lentivirus, vascular-endothelial cadherin, endothelial differentiation. 
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Resumo 
 
 O conhecimento na área da diferenciação de células estaminais na linhagem endotelial 
tem registado, nos últimos anos, um crescimento muito acentuado. Este fenómeno surge quer em 
consequência da relevância das células endoteliais na prática clínica, quer do potencial que, por 
esse motivo, representam enquanto fonte celular para uso em técnicas de medicina regenerativa, 
como por exemplo, na recuperação de condições como a isquémia.    
 No entanto, apesar da diferenciação endotelial constituir uma área activa de pesquisa, 
este processo continua a ser ineficiente). A baixa eficiência dos processos de diferenciação 
endotelial está associada com a falta de estandardização do processo, tanto quanto ao tipo de 
células a diferenciar, bem como as condições de cultura (factores de crescimento, citocinas, 
matrizes extracelulares). Com o intuito de desenvolver metodologias para colmatar esta lacuna, 
têm sido desenvolvidos sistemas virais que permitem a monitorização da expressão de genes de 
interesse.) 
Neste contexto, o objectivo central deste projecto foi o desenvolvimento de uma ferramenta 
lentiviral que permitisse a monitorização da expressão da vascular-endothelial cadherin (VE-
cadherin) (marcador endotelial tardio). Na construcção deste sistema lentiviral, o promotor da 
VE-cadherin foi associado a uma porção de DNA codificante para uma proteína fluorescente 
vermelha (mCherry).  
 A validação desta ferramenta foi efectuada com infecção de human umbilical vein 
endothelial cells (HUVECs) e em células estaminais de pluripotência induzida (iPSCs). Os 
resultados relativos a estas infecções mostram que, 5 dias após a infecção, as HUVECs 
apresentam uma alteração positiva a nível da fluorescência vermelha e nenhuma alteração foi 
registada a nível das iPSCs infectadas. Neste momento está em curso a diferenciação das iPSCs 
infectadas e os níveis de fluorescência estão a ser monitorizados.  
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 Adicionalmente, foram gerados alguns dados relativos à internalização de nanopartículas 
orgânicas (NPs) e adesão e proliferação de iPSCs em matrizes extracelulares com potencial 
indutor para diferenciação endotelial. Resultados preliminares mostram que as iPSCs são 
capazes de internalizar as NPs mesmo quando estas se encontram aderidas ao substrato. 
 Sumariamente, os resultados mostram que a geração do sistema lentiviral desejado foi 
atingida com sucesso. Assim, futuramente, esta ferramenta poderá mostrar-se extremamente útil 
na monitorização da diferenciação endotelial utilizando diferentes contextos extracelulares 
(factores de crescimento, citocinas, matrizes) e utilizando diferentes fontes de células. Acresce 
que esta ferramenta poderá não abranger apenas o contexto de células estaminais mas também 
expandir-se para outras populações celulares e estudar nomeadamente processos de 
transdiferenciação. 
 
 
Palavras-chave: lentivírus, diferenciação endotelial, vascular-endothelial cadherin 
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1. Introduction 
 
Within the last years the knowledge regarding stem cells (SCs) has suffered an exponential 
growth. Processes like stem cell self-renewal, proliferation, differentiation and embryonic 
development are becoming more clear and constitute active research fields. Recently, some 
advances in the field of SCs enabled the artificial reprogramming of differentiated cells into a 
pluripotent state (induced pluripotent stem cells - iPSCs) and opened new ways for potential 
translation of stem cell technology into regenerative medicine. 
This section introduces the general stem cell characteristics and also specifies some of 
the characteristics of embryonic stem cells (ESCs) and iPSCs.  
1.1. Stem cells 
 
 
Stem cells have two unique properties: the capacity of self-renewal and the 
differentiation potential (Mountford, 2008).   
 
Figure 1 - Asymmetrical and symmetrical stem divisions (Mountford, 2008). 
 
The self-renewal capacity is responsible for the replacement of stem cells and avoids 
their exhaustion. This mechanism can be accomplished by symmetric cell division when a stem 
cell gives rise to two daughter cells that maintain their stemness or by asymmetrical cell division 
when one stem cell originates a differentiated cell and another stem cell (Figure 1) (Mountford, 
2008).. 
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The hierarchic classification of SCs takes into account their differentiation potential: 
from the most primitive cells to cells with a more restricted capacity of differentiation.  
Pluripotent stem cells are characterized as able of unlimited self-renewal and can give rise to 
every cells present in every tissue of the adult body (Eckfeldt, Mendenhall & Verfaillie, 2005). 
 
The stem cell behaviour is regulated by intrinsic and extrinsic signals in a complex 
network of interactions. The regulation of stemness comprises environmental stimulus, 
transcriptional regulation, post transcriptional regulation, genetic and epigenetic control 
mechanisms that decide the fate of SCs (Figure 2) (Jaenisch & Young, 2008).. 
 
Figure 2 – Schematic representation of a transcriptional regulatory circuitry of 
pluripotency and possible connections between signal transduction pathways, 
transcription factors (blue circles), chromatin regulators (green circles) and their 
target genes (orange squares) (Jaenisch & Young, 2008). 
 
The major regulators of self-renewal, pluripotency, differentiation and viability of human 
ESCs (hESCs) and pluripotent SCs (PSCs) involve signalling pathways like transforming 
growth factor β (TGF-β), receptor tyrosine kinase (RTK), wingless (Wnt), bone morphogenetic 
proteins (BMP) and others (Figure 3). The maintenance of pluripotency is associated with 
expression of genes such as octamer-binding 4 (Oct4), homeobox protein Nanog, sex 
determining region Y box 2 (Sox2), krueppel-like factor 4 (Klf4), stella (Dppa3), zinc finger 
protein 42 (Rex1) and gastrulation brain homeobox 2 (Gbx2). Furthermore hESCs have a 
characteristic pattern of surface markers that allow their recognition, like stage-specific 
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embryonic antigens (SSEAs) 3 and 4 (SSEA 1 negative), TRA-1-60, TRA-1-81, GTCM-2 and 
alkaline phosphatase (Pera & Tam, 2010). Additionally also extrinsic mechanisms have an 
important role in the fate of ESCs. In this way, the microenvironment where SCs are included 
named niche has also a central role in the SCs fate and control of self-renewal, survival and 
differentiation. 
 
Figure 3 - Illustration of signalling cascades that regulate self-renewal, differentiation 
and viability (Pera & Tam, 2010). 
 
Table I  – Lineage specific differentiation of hESCs (Mountford, 2008) 
 
 
In the stem cell field, one of the major steps resulted from research done by Evans, 
Kaufman and Martin that culminated in the isolation of embryonic stem cells in 1981 from the 
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inner cell mass (ICM) of mouse blastocyst (Katsumoto, Shiraki, Miki & Kume, 2010) and 
isolation and characterization of hESCs in the late 1990 by Thomson and colleagues (Eckfeldt, 
Mendenhall & Verfaillie, 2005).. Although the differentiation process is not yet a fully defined 
mechanism there are already several protocols that allow the successful differentiation of hESCs 
into specific cell lineages (table1). 
Recently, Shinya Yamanaka and colleges achieved the reprogramming of differentiated 
human fibroblasts into iPSCs (Takahashi et al., 2007). Since then, several cell types have been 
generated from iPSCs, like human secreting insulin cells, human cardiomyocytes and human 
hematopoietic cells. iPSCs resemble ESCs in genomic, transcriptomic and epigenomic patterns 
and provide a way to study the mechanisms involved in reprogramming, lineage commitment 
and cellular differentiation (Hipp & Atala, 2008).. The reprogramming induction can be 
considered a two-stage process that initially embraces the inhibition of genes associated with the 
lineage specification and reversion of the epigenetic pattern associated with differentiated cells. 
While in the second stage, when the cell is partially reprogrammed, the exogenous 
reprogramming factors (RFs) will reactivate the transcriptional network responsible for 
pluripotency. The induced reprogramming of somatic cells into pluripotent cells involves a 
complex transcriptional network that may include octamer-binding 4 (Oct4) (Amabile & 
Meissner, 2009;), sex determining region Y box 2 (Sox-2), krueppel-like factor 4 (Klf4) 
(Spagnoli & Hemmati-Brivanlou, 2006) and c-Myc (Hipp & Atala, 2008; Spagnoli & Hemmati-
Brivanlou, 2006; Wang & Steinbeisser, 2009). 
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Figure 4 - A) Oct4, Sox2 and Nanog target genes and respective functions.; B) The 
reprogramming mechanism as a two-stage process (Adapted from Schemer & Copra, 
2009). 
 
1.2. Differentiation 
 
 
A better understanding of cellular differentiation and respective regulatory mechanisms 
is essential for the advance of the cell-based therapy of a broad spectrum of diseases. The SC 
manipulation and specially iPSCs can be the mean to generate this knowledge and contribute to 
a future improvement of the utilization of SCs in regenerative medicine (Spagnoli & Hemmati-
Brivanlou, 2006). 
In this section, the differentiation processes that occur during the embryonic 
development and also the strategies used to induce differentiation of SCs into the vascular 
lineage will be pointed out. 
 
1.3. Mechanisms of differentiation in embryonic development 
 
 
During embryogenesis the initial fertilized egg gives rise to the morula, where the first 
event of differentiation takes place when the trophectoderm lineage is established with 
A B 
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associated expression of trophectoderm markers, such as caudal-related homeobox 2 (Cdx2). 
Posterior divisions originate the blastocyst stage, where the second developmental decision 
occurs in the inner cell mass (ICM), within the blastocyst. The ICM differentiates into the 
epiblast (also known as the primitive ectoderm) and the primitive endoderm, where is thought 
that Nanog may have a central role by induction of epiblast markers expression (e.g. FGF5) and 
downregulation of markers of both the primitive endoderm (e.g.GATA4 and GATA6) and the 
ICM (e.g. Rex1 and Gbx2) (Spagnoli & Hemmati-Brivanlou, 2006).   
The next embryonic developmental stage is the gastrulation and during this period 
several changes occur in cell motility, cell polarity, cell shape and cell adhesion (Wang & 
Steinbeisser, 2009). During this stage the pluripotent epiblast cells are allocated to the three 
primary germ layers, ectoderm, mesoderm and endoderm. These three germ layers will give rise 
to all types of cells that integrate the different adult tissues (Figure 5).  
 
 
Figure 5 - Lineage differentiation within the inner cell mass during the normal 
embryogenesis (Spagnoli & Hemmati-Brivanlou, 2006). 
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Within the mesodermal differentiation, the endothelial progenitor cells (EPCs) share a 
common precursor cell with hematopoietic cells, the hemangioblasts. EPCs can also be derived 
from vascular progenitor cells (VPCs) and further differentiation processes from EPCs and 
VPCs into endothelial cells (ECs) depends on location in the embryo, access to specific factors 
(VEGF, Wnts, BMP and others) and paracrine signaling from the neighbouring stem/progenitor 
or even differentiated cells.(Figure 6) (Luo et al., 2011; Bai & Wang, 2008). 
 
 
Figure 6 -.Progenitor cells driving endothelial cells (Luo et al., 2011) 
  
1.4. Vascular lineage differentiation 
 
The vessel formation is a complex mechanism that occurs during embryogenesis 
(Yancopoulos et al., 2000), tumoral angiogenesis, wound healing and after ischemic situations. 
The vessel formation comprises interactions between endothelial cells (ECs) and the mural cells 
(MCs) (pericytes and vascular smooth muscle cells -VSMCs) (Kitagawa & Era, 2010). 
The vessel formation includes various processes and signalling molecules and studies in 
this area may give some clues for optimization of vascular in vitro differentiation protocols. The 
main pathways involved in differentiation of vascular cells involve vascular endothelial growth 
factor (VEGF), angiopoietin, TGF, Wnt, Notch and ephrin families (Yancopoulos, et al., 2000; 
Otrock et al., 2007). In addition to these factors there are other features that regulate the 
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angiogenic process such as soluble factors (e.g. TNF-α, HIF-1, angiogenin, angiotropin), 
membrane-bound factors (e.g. αvβ3-Integrin, vascular endothelial-cadherin) and the plasmin and 
metalloproteinase systems (Eble & Niland, 2009). 
1.4.1. Endothelial cells (ECs) 
 
In vitro generation of endothelial cells from PSCs can be achieved by either culturing as 
embryoid bodies (EB), by co-culturing with other cell lines or, as most recently described, by 
culturing SCs in defined chemical conditions followed by various culture manipulations 
including the addition of growth factors and cytokines, defined adhesion substrates, mechanical 
stress, and vascular progenitor cell isolation and culturing.  
Within the endothelial differentiation process there are several signalling pathways like 
VEGF, Wnt and Notch, TGF-β family, together with ROS signalling and microRNAs that play 
an important role in the differentiation process (Figure 7).  
Regarding the VEGF family it is composed by 5 members, VEGF-A, VEGF-B, VEGF-
C, VEGF-D and placenta growth factor (PIGF) and several alternatively spliced isoforms. 
VEGF-A is the most potent pro-angiogenic protein and is involved in proliferation, sprouting 
and formation of endothelial cell’s tube, it is a crucial mediator of early vascular formation and 
has also an essential regulatory role in post-natal angiogenesis. This molecule interacts with both 
specific tyrosine kinase receptors, VEGFR1, also known as Fms-like tyrosine kinase-1 (Flt-1) 
and VEGF-R2 also known as Kinase insert domain receptor (KDR). Additionally, VEGF-A also 
binds to the neuropilin-1 receptor (NP1), in a complex which promotes the binding to VEGF-R2. 
VEGF-R2 is the major mediator of VEGF induced responses (Luo et al., 2011). 
The VEGF/VEGF-R2 axis mediated EC differentiation, proliferation and migration 
involves several signaling pathways (Figure 7). After ligand binding, VEGF-R2 induces receptor 
phosphorylation and activation of the classical extracellular signal-regulated kinases (Erk) 
pathway, via a protein kinase C (PKC)-dependent pathway involving activation of 
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phospholipase C-γ (PLC-γ), activation of PI3K and subsequently activation of AKT and 
HDAC3 (Figure 7). There are also some reports involving Shb as a downstream molecule of the 
VEGF/VEGF-R2 axis, and as an amplifier of the VEGF-R2 signal. 
 
 
Figure 7 – Signaling pathways involved in the endothelial differentiation process 
(Luo et al., 2011). 
 
Another important growth factor family involved in EC differentiation is the TGF-β 
family that includes TFG- β, inhibins, activin, nodal, anti-müllerian hormone, BMP-2, 4, 6 and 
7, decapentaplegic and Vg-1. It has been demonstrated that TFG-β promotes the generation of 
ESC-derived EC progenitor cells through transcription factor snail and additionally a very recent 
report has demonstrated that inhibition of TGF-β signaling in the late phase of endothelial 
differentiation resulted in the up-regulation of Id1 that consequently increases the yield of ECs 
from hESCs. Interestingly, this study also found that TGF-β inhibition helped to consolidate the 
endothelial identity of the isolated ECs and also maintained proliferation for an extended period. 
On the other hand, in early endothelial cell commitment TGF-β plays a role and without this 
factor there is no vascular commitment (James, et al., 2010). 
 
Also the Wnt large family of cysteine-rich secreted proteins is involved in an array of 
diverse processes such as embryonic growth, migration, and differentiation. Wnt signaling 
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controls cell proliferation, stemness maintenance, stem cell fate decisions, organized cell 
movements and the establishment of tissue polarity. The relevance of this pathway in the 
embryonic vascular development was shown by knockout mice studies reporting that β-catenin 
or Wnt co-receptors deficient mice fail to develop the mesoderm layer (Luo et al., 2011).   
In addition to growth factors, there are also other factors like ROS and microRNAs that 
have an important role in the EC differentiation. ROS are important determinants of vascular 
function, acting not only as activators of cell growth and differentiation but also as modulators 
in pathological processes. As intracellular second messengers, ROS can activate several 
signaling molecules and pathways (G proteins; Src, Ras, JAK2, Pyk2, PI3K, and MAPK 
pathways), inhibit protein phosphatases, modify the activity of phospholipases, alter intracellular 
cation concentrations, and regulate expression and function of transcription factors such as 
NFκB, activator protein-1, and hypoxia inducible factor-1. Along with these angiogenic 
regulators, miRNAs and specially a family of angiogenic miRNA (Fish & Srivastava, 2009) can 
also modulate the expression of key angiogenic related molecules.  
 
1.5. Strategies to induce in vitro differentiation of stem cells into endothelial cells 
 
The in vitro differentiation may be achieved with different protocols for SCs according 
to the culture method (Kitagawa & Era, 2010) embryoid body (EB) formation, culture on feeder 
cells, chemical defined culture mediums (growth factors, cytokines), and more recently the use 
of nanotechnology and biomaterials are fields of expanding knowledge regarding manipulation 
of SC fate and differentiation. 
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Figure 8 - Factors that control the differentiation processes within the embryoid 
bodies (Bratt-Leal, Carpenedo et al. 2009). 
 
Although presently there is no standardized protocol to generate stem/ progenitor cell-
derived endothelial cells (Kane et al., 2011), there are two major approaches in order to obtain 
ECs: the 3D embryoid body (EB) differentiation or 2D monolayer directed differentiation, 
associated with different serum and growth factor and cytokine differentiation media and 
different cellular sub-populations enrichment (either by FACS or MACS -). More recently the 
use of nanotechnology and biomaterials are also active research areas that are trying to 
contribute to improve the efficiency of the endothelial differentiation protocols (Ferreira et al., 
2007a). 
EB formation is a method widely used to examine the differentiation potential of SCs 
and offers the opportunity to study early three-dimensional assembly of pluripotent cells. The 
cells are cultured using different methods for embryoid body formation such as hanging drop 
method, static suspension cultures, entrapment systems like hydrogels (methylcellulose, fibrin or 
hyaluronic acid) and use of multi-well and microfabrication technologies (e.g. microwells, 
microfluidic chambers) (Ng et al., 2005). The differentiation of EBs is coordinated by factors 
like the size and three-dimensional organization of EBs, the microenvironment, cell-cell 
interactions and extracellular matrix interactions (Figure 13).  Nevertheless, the formation of 
EBs triggers spontaneous differentiation of all cell types, it is an inefficient method with low 
endothelial differentiation yields (ranging from 1 to 3% for ECs) (Levenberg et al., 2002; Cho et 
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al., 2007; Li et al., 2008 ; ; Kane et al., 2011) because controlling the microenvironment within 
the EB is still a very difficult task (Blancas, Lauer & McCloskey, 2007). In order to circumvent 
the disadvantages and make the most of the advantages of EB based differentiation several 
groups reported mixed strategies that combine EB technology with other endothelial induction 
methods. Improved differentiation efficiencies were obtained with supplementation with 
angiogenic factors like VEGF-A (Blancas, Lauer & McCloskey, 2007; Ferreira et al., 2007; 
Nourse et al., 2010), amplification of EB derived homogeneous sub-populations with endothelial 
differentiation potential (PECAM-1, CD34, KDR) (Ferreira et al., 2007 ) (Levenberg et al., 
2002; Ferreira, et al., 2007; Kane et al., 2011), hypoxia (Prado-Lopez et al., 2010) and 
suppression of the TGF-β pathway (James et al., 2010; Kane et al., 2011).. Also the use of 
different cell sources for endothelial differentiation has been an important field of study. The use 
of some progenitor cells (like endothelial progenitor cells EPCs) might constitute a way to 
improve the endothelial differentiation process by exploring the susceptibility of endothelial 
differentiation of specific stem cell populations (Eggermann et al., 2003; Dimmeler et al., 2001).  
Recently the use of micropatterned extracellular matrix islands was shown to provide a 
way to reduce in some degree the heterogeneity of the differentiation process based in EB 
culture (Bauwens et al., 2008). In this study (Bauwens et al., 2008) EBs (with different sizes) 
were generated from different sized hESCs colonies and a connection was found between 
hESCs colony size, EBs size and propensity to mesodermal commitment. Larger EBs derived 
from hESCs small colonies were associated to higher mesodermal induction (Bauwens et al., 
2008) 
 
Regarding the 2D differentiation methods, these include co-culture with feeder layers 
like: mouse stromal cells (Vodyanik et al., 2005), mouse bone marrow stroma cells and mouse 
ECs (Vodyanik et al., 2005; Kaufman et al., 2001), prior to isolation and sub-culture. This type 
of differentiation strategies is associated with slightly higher efficiency in generating ECs 
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(around 10%) capable of forming durable vessels in vivo (Wang et al., 2007) but requires more 
laboratorial handling of the cells (separation from feeder-cells) and has a higher risk of 
contamination by non-human products. Recently a fast initiation method was described that 
employed a combination of matrix culture of  collagen IV and a differentiation medium 
containing stem cell factor (SCF), VEGF-A and β-FGF (Lagarkova et al., 2008). The ECs 
generated in this study (Lagarkova et al., 2008) expressed immunological markers (vWF, 
CD105), endothelial specific genes (vascular endothelial-cadherin, KDR, endothelial nitric 
oxide synthetase), and formed endothelial characteristic networks on collagen matrix and in 
Matrigel assay but still, in vivo functional data was not reported (Lagarkova et al., 2008).  
Very recently, a fully scalable feeder and serum-free method for the derivation of 
functional ECs without EB requirement was reported (Kane et al., 2010). The endothelial 
differentiation medium was supplemented with hydrocortisone, human epidermal growth factor, 
basic fibroblast growth factor and heparin (Kane et al., 2010). This study showed a rapid 
downregulation of pluripotency factors, concomitant with induction of vascular endothelial 
markers at the mRNA, miRNA, and protein levels. Moreover, the derived ECs respond to an NO 
stimulator, migrate, and spontaneously produce tube-like structures in monolayer cultures and 
when cultured in 3D matrices (Matrigel). The in vitro differentiated cells (10 days) were 
efficient at the induction of therapeutic neovascularisation and were incorporated into the blood 
perfused vasculature of recipient mice (Kane et al., 2010). 
Biomaterial engineering as also contributed to the development of new means to achieve 
in vitro generation of endothelial cells and highlighted the importance of integration of 
biological and physicochemical sciences. These biological modalities in scaffold design fall into 
three major categories: those that mimic the original tissue architecture and strength, those that 
enable cell adhesion, and those that induce or contribute to the maintenance of cell phenotype 
(Krenning et al., 2008). Some of the elements from the extracellular microenvironment that may 
be incorporated into biomaterials to achieve their biological activity may include insoluble 
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extracellular matrix (ECM) macromolecules, diffusible molecules, and cell–cell receptors 
(Shekaran & Garcia, 2011). The current challenge of biomaterial engineering is to achieve the 
combination the all of these biological moieties and therefore mimic the native 3D complex 
biological microenvironments. The use of this kind of strategy will contribute to minimize 
adverse effects that biomaterials may have on the differentiating cells (Krenning et al., 2008). 
These bioinspired approaches have been applied in the development of biomaterials capable of 
directing specific cell functions (Shin, Jo & Mikos, 2003; Mann et al., 2001) and controlled 
degradation in a 3-D matrix (Lutolf et al., 2003; Raeber, Lutolf & Hubbell, 2005; Lutolf & 
Hubbell, 2005). 
The screening of biomaterials and cell interactions is a time consuming process but to 
circumvent this hurdle new screening approaches based on microarray techniques and 
combinatorial libraries of polymeric biomaterials have arisen. (Bailey, Sabatini & Stockwell, 
2004; Anderson, Burdick & Langer, 2004; Meredith et al., 2003). Some groups used  robotics 
technology and produced a polymer microarray featuring three blocks of 1152 polymers 
(Anderson et al., 2005) , a similar technique was used to generate micro arrays for 576 different 
combinations of acrylate-derived monomers, and their interactions were investigated for 
embryonic stem cell (hESCs) growth and differentiation (Anderson, Levenberg & Langer, 
2004). A microarray platform was developed for the culture of patterned cells on top of 
combinatorial matrix mixtures, enabling the study of differentiation in diverse 
microenvironment situations in parallel. The fabrication process used a standard robotic DNA 
spotter to form the cellular microarray that provides a 32 extracellular matrix combination of 
collagen I, III, IV, laminin, and fibronectin. The effect of these combinations was evaluated in 
terms of cellular differentiation in two contexts: maintenance of primary rat hepatocyte 
phenotype and differentiation of mouse embryonic stem (ES) cells toward an early hepatic fate 
(Flaim, Chien & Bhatia, 2005). One of the main advantages of this platform is that it can be 
easily adapted to other applications like cell differentiation towards other lineages, like the 
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endothelial. Another microarray-based screening system was developed for testing the effects of 
small molecules entrapped within the disc polymer were the cells are then seeded (Bailey, 
Sabatini & Stockwell, 2004). 
 
While some cell types retain tissue-specific features on 2-D surface, it has become 
increasingly apparent that a 3-D physical environment will be required for others (Albrecht et 
al., 2005). Therefore, micro-fabrication techniques have been employed to fabricate 3-D 
microwells on a glass surface (Revzin et al., 2001)  and also the combination of micro-
patterning with the use of hydrogels to retain cells within a 3-D microenvironment (Liu & 
Bhatia, 2002; Albrecht et al., 2005). With these 3-D microarrays, multiple cell types were 
encapsulated within a confined 3-D geometry that maintained them in a viable and proliferative 
state for a few days (Liu & Bhatia, 2002; Albrecht et al., 2005). Although the approach is still in 
infancy, a 3-D microarray may be a next generation platform for the high throughput analysis of 
cellular responses to microenvironment components that resemble in vivo characteristics (Shin, 
2007). 
 
1.6. iPS derived endothelial cells 
 
With respect to hiPSC-differentiation into ECs, some studies have shown that iPSCs 
have the potential to originate this type of cells by assessing the expression of lineage specific 
markers, capacity of tube formation and other specific characteristics of ECs (Choi et al., 
2009a). However, the differentiation potential of iPSCs is still not yet fully characterized and it 
is not yet clear whether iPSCs undergo a series of cellular changes similar to hESCs following 
differentiation to specific lineages. iPSCs derived ECs exhibited a cobblestone-like appearance 
on culture dishes, were positive for eNOS, and showed to be positive for CD31 and VE-cadherin 
markers (Homma et al., 2010). Additionally, some hiPSC lines are capable of differentiation 
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into blood and endothelial cells with a differentiation pattern very similar to that observed with 
hESCs when co-cultured with mouse bone marrow stromal cell line OP9 (Choi et al., 2009b). 
Moreover, when applying the same differentiation method to iPSCs and hESCs, derived ECs 
showed a expression of endothelial-related genes like VE-cadherin, CD31, von Willebrand 
factor (vWF), and CD34 at levels similar to those seen in adult ECs (Taura et al., 2009). 
 
1.7. Objectives 
 
The main aim of our project comprised the generation of a tool of molecular and cellular 
biology that allows an efficient and specific high throughput screening method for endothelial 
differentiation.  Additionally, other goal of this project embraced the characterization of possible 
means (nanoparticle internalization and culture in different substrates) to improve the efficiency 
of the endothelial differentiation process. 
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2. Material and Methods 
 
2.1. Cell culture 
 
2.1.1. iPS cell culture 
 
The iPSCs were gently given by Ulrich Martin (reprogrammed from cord blood cells) 
(Haase, et al., 2009) These cells were cultured in a first phase in inactivated mouse embryonic 
fibroblasts (MEFs) and then cultured in a feeder-free system as described below.  
The inactivation of MEFs was preceded by MEFs expansion where these cells were 
grown in Dulbecco's Modified Eagle's Medium (DMEM - Sigma) and 50% fetal bovine serum 
(FBS) (Invitrogen) and penstrep (Invitrogen). After 2 passages the MEFs were inactivated with 
7mL of mitomycin C (8 microg/ mL Invitrogen) per T75 flask during 2 hours and 30 minutes.  
The iPSCs were cultured in DMEM KO (Gibco), 20% KO serum replacement (Gibco), 
5mL glutamine (Invitrogen), 1mL mercaptoethanol (Sigma), 250μL β-FGF (Prepotech), 5 mL 
non-essential aminoacids (Invitrogen) penstrep (Invitrogen) (iPS medium) when co-cultured 
with MEFs.  
To transfer the iPSCs from the feeder system to a feeder-free system we used a magnetic 
assorted cell sorting (MACS) with CD326  antibodies (Milteny) (as schematized in 
Figure 9). After detaching the iPSCs with trypsin (Invitrogen), the iPSCs were 
ressuspended in iPSCs medium with ROCK inhibitor (10µL/mL) to avoid apoptosis during the 
sorting process; the beads were added and mixed well. This mixture was incubated 15 minutes at 
4ºC and washed with 2mL of iPS medium with ROCKi (10µL/mL). After washing the MACS 
column 3 times with 500µL of iPS medium the cell suspension was applied to the column and 
washed 3 times with 500µL of iPS medium. In the final step the iPSCs were collected in 1mL of 
iPS medium with ROCKi (Cayman) (10µL/mL) and plated in matrigel (BD) with iPS medium 
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previously conditioned by inactivated MEFs (supplemented with ROCKi 10µM and βFGF 
10µM).  
 
 
Figure 9 - Schematic representation of the MACS separation protocol (adapted 
from MACS handbook) 
 
2.1.2. iPSCs characterization 
 
2.1.2.1. Immunostaining  
 
Immunofluorescent labelling of the iPSCs was performed to characterize the expression 
of pluripotency markers such SSEA-4, TRA-1-60 and TRA-1-80 antibodies (Cell 
Technologies). The cells were fixed with 4% paraformaldehyde (PFA) at room temperature 
during 15 minutes in glass coverslips coated with matrigel (BD), washed 1 time with phosphate 
buffered saline (PBS) followed by a blocking step with PBS with 5% bovine serum albumin 
(BSA - Sigma) and 2% FBS for 30 minutes at room temperature. The incubation with the 
iPSCs and MEFs 
suspension 
Magnetic labelling of 
iPSCs (CD326+) 
Wash: 3x 500µL with 
iPS medium 
Apply the cell 
suspension (500µL of 
each time) Wash: 3x 500µL with 
iPS medium 
Elute iPSCs with iPS medium 
MS column 
MACS separator within 
the magnetic field 
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primary antibody (dilution factor 1:100) at room temperature during 60 minutes was followed 
by 3 washes with PBS and incubation with the secondary antibody (dilution factor 1:200) for 
other 60 minutes at room temperature. After the secondary antibody incubation the cells were 
washed 3 times with PBS, fixed with 4% PFA for 5 minutes at room temperature. The coverslips 
containing the cells were then stained with DAPI and mounted with mounting medium (Dako) 
 
2.1.2.2. Nanoparticle internalization in iPSCs and adhesion to different substrates 
 
After sterilization of the glass coverslips with ethanol 70% and UV light during 30 
minutes the different coating protocols were performed (Table IITable II –). Some coatings were 
performed using a layer-by-layer method and in some cases the hyaluronic acid (HA) was 
integrated within other substrates (gelatine and matrigel). 
Regarding the matrigel coating, the matrigel (BD) was thawed overnight at 4ºC and then 
diluted (1:50) in DMEM (Gibco) with ROCK inhibitor (Cayman 10µM). The coverslips were 
coated with matrigel solution during 30 minutes at 37ºC, and washed with PBS (Sigma).  
Concerning the hyaluronic acid (HA) coating, 500µL of HA solution (5mg/mL in 0,15M 
NaCl 20mM HEPES buffer - pH 7,4 ) were added to each condition and incubated overnight at 
37ºC. In some cases the HA was incorporated within other substrates (gelatine, matrigel) and not 
assembled by layer deposition. The excess of HA was aspirated and rinsed 1 time with PBS 
(Sigma) 
Regarding the protamine sulfate (PS) coating, 500µL of PS solution (10mg/mL in PBS) 
were added to each condition and incubated during 20 min at 37ºC in order to make a layer-by-
layer coating when other substrates were present. The excess of PS was aspirated and washed 1 
time with PBS (Sigma). 
Regarding the poly-dopamine coating , the coverslips were washed in 20 mL of 
methanol:water (1:1) for 10 minutes and then the coverslips were transferred to acetone for 10 
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minutes. The coverslips were dried and immersed  into a dopamine.HCl solution (2mg/mL of 
10mM Tris - pH 8,5) in a 24 well plate at 25ºC during 12-18 hours with agitation. The 
coverslips were then rinsed with deionised water and dried.  
Regarding the methylcellulose coating, were added 500µL of a 5% solution of 
methylcellulose and incubated at 37ºC for 20 minutes. The excess of this solution was aspirated 
and rinsed 1 time with PBS (Sigma). 
In the conditions with nanoparticles (NPs) adhered to the platforms a NP solution of 
500µg/mL was used; 1mL of NP solution was added to the platform and centrifuged for 10 
minutes at 4000rpm, followed by 2 washes with 500µL of PBS (Sigma) .In the conditions with 
nanoparticles in suspension a NP solution of 5mg/mL was used and 1mL of solution was added 
to each condition 2 hours after platting the cells. 
 
Table II – Generation of different substrates for iPSCs culture 
Second layer 
substrate  
Nanoparticles First layer substrate 
Mixed substrate NP+ NP- 
None -------------- ------------ 
None adhered adhered 
Protamine Sulfate adhered 
suspension 
------------- 
Glass coverslips 
Protamine Sulfate 
Hyaluronic Acid 
-------------- 
adhered 
suspension 
None -------------- ------------ Matrigel 
None adhered 
suspension 
adhered 
suspension 
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Hyaluronic Acid adhered 
suspension 
adhered 
suspension 
None -------------- ------------ 
None adhered 
suspension 
adhered 
suspension 
Hyaluronic Acid 
-------------- 
adhered 
suspension 
Protamine Sulfate adhered 
suspension 
------------- 
Poly-dopamine 
Protamine Sulfate 
Hyaluronic Acid 
-------------- 
adhered 
suspension 
None -------------- ------------ 
Protamine Sulfate adhered 
suspension 
------------- 
Gelatine (1%) in PBS 
(pH=7,4) 
(Gelatin1) 
Protamine Sulfate 
Hyaluronic Acid 
-------------- 
adhered 
suspension 
None -------------- ------------ 
Hyaluronic Acid 
-------------- 
adhered 
suspension 
Gelatine (1%) in NaCL 
HEPES buffer (pH=4,6) 
(Gelatin2) 
Hyaluronic Acid 
incorporated (inc) 
 -------------- 
adhered 
suspension 
None -------------- ------------ 
Hyaluronic Acid 
-------------- 
adhered 
suspension 
Gelatine (1%) in PBS 
(pH=4,6) 
 
(Gelatin3) Hyaluronic Acid 
-------------- 
adhered 
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incorporated (inc) suspension 
Protamine Sulfate 
Hyaluronic Acid 
-------------- 
adhered 
suspension 
Methylcelulose (5%) Protamine Sulfate 
 
adhered 
suspension 
adhered 
suspension 
 
 
2.1.3. HUVEC cell culture 
 
The human umbilical vein endothelial cells (ATCC) were cultured in EGM2 
(Lonza).  
 
2.1.3.1.  HUVECs characterization 
 
2.1.3.2. Immunostaining  
 
Immunofluorescent labelling of HUVECs was performed to characterize the expression 
of endothelial characteristic markers such CD31 () and VE-cadherin (). The cells were fixed 
with 4% paraformaldehyde (PFA) at room temperature during 15 minutes in glass coverslips 
coated with gelatine (0,1%), washed 1 time with phosphate buffered saline (PBS) followed by a 
blocking step with PBS with 5% bovine serum albumin (BSA - Sigma) and 2% FBS for 30 
minutes at room temperature. The incubation with the primary antibody (dilution factor 1:100 – 
VE-cadherin – Santa Cruz and 1:50 CD31 - Sigma) at room temperature during 60 minutes was 
followed by 3 washes with PBS and incubation with the secondary antibody (dilution factor 
1:200) for other 60 minutes at room temperature. After the secondary antibody incubation the 
cells were washed 3 times with PBS, fixed with 4% PFA for 5 minutes at room temperature. The 
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coverslips containing the cells were then stained with DAPI and mounted with mounting 
medium (Dako). 
 
2.1.3.3. Blasticidin selection  
 
To perform the blasticidin selection cell culture medium was supplemented with 
different amounts (5µg/mL; 10µg/mL; 25µg/mL for HUVECs and 5µg/mL; 8µg/mL; 10µg/mL; 
20µg/mL for iPSC) of blasticidin (Invitrogen).  
 
2.1.4. 293T cell culture 
 
The human embryonic kidney cell-line (293T - ATCC) was grown in DMEM (Gibco) 
with 10% fetal bovine serum (Sigma) and penicillin, streptomycin sulfate, and amphotericin B 
(Invitrogen). 
 
2.2. Cloning experiments 
 
To generate the construct of interest with a vascular endothelial cadherin promoter 
tagged with a fluorescent protein (mCherry) and with a blasticidin resistance gene we used three 
clones with the respective sequences in annex I. 
 
2.2.1. Generation of the VE-cadherin promoter cherry lentiviral plasmid 
 
The three clones listed below were used to generate the VE-cadherin promoter cherry 
fusion construct. The cloning strategy is described in detail below. 
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2.2.1.1.  Plasmids used to create the final construct 
 
 pCR TOPO II mcherry: 4071bp 
 plenti6 ires egfp: 8274bp 
 VPr-GFP construct: 8712bp 
 
2.2.1.2. Transformation of DH5α and XL2 blue competent cells 
 
To transform the competent cells (DH5α competent cells - Invitrogen or XL2 blue 
ultracompetent cells – Aggilient Technologies), with different target DNA sequences, the 
competent cells were thawed on ice and aliquoted into 50µL in a 1,5mL microcentrifuge tube 
(on wet ice). The DNA of interest was added to the cells (1µL- approximately 1ng) and 
incubated on ice during 30 minutes. The cells were heat shocked for 40 seconds at 42ºC and 
placed on ice during 2 minutes. For the recovery of the competent cells 450µL of Luria Bertani 
(LB) medium was added to each tube and incubated at 37ºC for 1 hour. The cell suspension was 
then plated on ampicilin selection plates and incubated at 37ºC overnight. 
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2.2.1.3. Restriction cloning strategy 
2.2.1.3.1. First step of the cloning process 
 
 
Figure 10 – Schematic representation of the first cloning step. 
 
2.2.1.3.1.1  Confirmation of the orientation of the fragment of interest (VE-promoter) 
Fragment of interest1 
VE-cadherin promoter 
Fragment of interest2 
Mcherry backbone 
 
Ligation of 
the fragments 
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Figure 11 – Schematic representation of the strategy used to confirm the 
integration of the VE-promoter. 
 
 
 
Figure 12 – Schematic representation of the strategy used to confirm the orientation 
of the integration of the VE-promoter and mCherry. 
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2.2.1.3.1.2 Second step of the cloning process 
 
 
Figure 13 – Schematic representation of the second cloning step (first strategy). 
 
 
 
Fragment of interest3 
VE-cadherin promoter-mCherry 
Fragment of 
interest PLenti6V5 
Ires EGFP 
No colonies after ligation 
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Figure 14 - Schematic representation of the second cloning step (definitive strategy) 
 
Fragment of interest 
PLenti6V5 Ires EGFP 
Fragment of interest3 
VE-cadherin promoter-mCherry 
Ligation of 
fragments 
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Figure 16 – Schematic representation of the strategy used to confirm the integration 
of the VE-promoter and mCherry fragments. 
 
 
2.2.1.3.2. Restriction enzyme assays 
 
The restriction enzyme reactions were performed in the buffers suggested by the 
company (New England Biolabs) for each enzyme used as shown in Table III. 
Table III – Conditions used to the different restriction digestions. 
Enzyme NEB buffer  Temperature of reaction Time of reaction 
HindIII Buffer 2 37ºC 4 hours 
BamHI Bam/Sal buffer 37ºC 4 hours 
NotI Buffer 2 37ºC Overnight 
EcoRI Ssp buffer 37ºC 3 hours 
EcoNI Buffer 4 37ºC 3 hours 
HpaI Buffer 4 37ºC 4 hours 
ClaI Buffer 4 37ºC 4 hours 
PspOMI Buffer 4 37ºC 4 hours 
T4 DNA Ligase T4 DNA ligase Room temperature  1 hour  
 
To blunt cohesive ends we used Klenow large fragment polimerase in 120µL reactions 
with 10µL dNTPs (10mM) and 1µL of klenow large fragment. 
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2.2.1.4. Desalting the DNA digest  
 
The QIAEX II Gel extraction kit from QIAGEN was used to desalt the DNA digest 
products from one restriction digestion so that a different restriction enzyme and buffer could be 
used in the next restriction steps. According to the size of the DNA fragments, 3 volumes of 
solution of buffer QX1 (solubilisation and binding buffer) (≤4 kb) or 3 volumes of buffer QX1 
plus 2 volumes of H2O (4–10 kb) were added to the DNA digestion products. After 
ressuspending the silica particles (QiAEXII), by vortexing, 10µL of QIAEX II were incubated at 
room temperature 10 minutes with the previous mixture. This suspension was then centrifuged 
30 seconds at 13000rpm and the pellet washed twice with 500µL of buffer PE (wash buffer). 
The pellet was then air dried for 10-15 minutes. The DNA elution was done in 20 µL of H2O by 
incubation during 5 minutes at room temperature (for DNA fragment ≤4 kb) or 50ºC (for DNA 
fragments with 4–10 kb), followed by a centrifugation of 30 seconds at 13000rpm and posterior 
recovery of the supernatant into a clean tube. An aliquot of the final DNA solution was run in a 
1,2% agarose gel to ensure that the DNA was properly purified. The schematic version of the 
protocol is presented in Figure 17. 
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Figure 17 - Schematic representation of the strategy used to purify DNA digests 
(adapted from QIAEX II Gel extraction kit QIAGEN handbook) 
 
2.2.1.5. DNA purification from starter cultures 
 
To start a maxiculture a single colony was picked and incubated in 2mL of LB medium 
with ampicilin overnight at 37ºC with an agitation of 220rpm. 
To purify DNA from bacterial starter cultures the QIAGEN QIA mini spin kit was used.  
After an overnight incubation, 1,5mL of the bacterial cultures were centrifuged (1,5mL 
microcentrifuge tube) at 13000 for 1 minute. The pellets were ressuspend in 250µL of buffer P1 
(ressuspension buffer) by vortexing and 250µL of buffer P2 (lysis buffer) were added and 
mixed. After 5 minutes of incubation 350µL of buffer N3 (neutralization buffer) were added and 
mixed by inverting the tube. This suspension was centrifuged during 10 minutes at 13000rpm 
and the supernatant was transferred to a QIAprep spin column. This suspension was centrifuged 
during 1 minute at 13000rpm and the flow-through was discarded. The QIAprep spin column 
was washed by centrifugation (1minute 13000rpm) with 500µL buffer PB (wash buffer) and the 
flow-through was discarded. The QIAprep spin column was washed by centrifugation (1minute 
13000rpm) with 750µL buffer PE (wash buffer). Another centrifugation was done (1 minute at 
13000rpm) to eliminate residues of buffer PE. The QIAprep spin column was placed in a 
DNA suspension + QIAEX II particles 
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microcentrifuge tube and 50µL of buffer EB (elution buffer) were added to the column. After 1 
minute of incubation at room temperature this suspension was centrifuged for 1 minute at 
13000rpm to elute the DNA. The schematic version of the protocol is presented in Figure 18. 
 
Figure 18 - Schematic representation of the strategy used to purify DNA from 
bacterial starter culture (adapted from QIA mini spin kit QIAGEN handbook) 
 
 
 
 
2.2.1.6. DNA purification from maxicultures 
 
After selecting the starter cultures of interest, bacterial maxicultures were established by 
incubating of 500µL  from the starter culture into 100mL of LB medium containing ampicilin  
and incubated at 37ºC overnight with a rotation speed of 220rpm. The DNA purification from 
bacterial maxicultures was done with QIAGEN HiSpeed Plasmid Midi Kit from QIAGEN. The 
bacterial cells were then harvested by centrifugation (4000rpm 5 minutes; 4ºC) and the bacterial 
pellet was ressuspend in 6mL of Buffer P1 (ressuspention buffer). The ressuspension step was 
followed by the addition of 6mL of buffer P2 (lysis buffer - mix by inverting 4-6 times) and 
 
Bacterial pellet 
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incubation for 5 minutes at room temperature. The inactivation of the bacterial lysis was 
achieved by addition and mix of 6mL of chilled buffer P3 (neutralization buffer). The bacterial 
lysate was then poured into the barrel of the screwed QIAfilter Cartridge and incubated during 
15-20 minutes at room temperature. The bacterial lysate was filtrated to a previously 
equilibrated (4 mL of buffer QBT) Hispeed Tip and the column was emptied by gravity flow. 
The column was washed with 20mL of buffer QC (wash buffer). To elute the DNA 5mL of 
buffer QF were pippeted into the column and the eluate was collected into a 15mL falcon. The 
DNA was precipitated by addition of 0,7 volumes of  isopropanol. The eluate/isopropanol 
mixture was filtered with a 20mL syringe attached to a QIA precipitator and washed with 2mL 
of 70% of ethanol. The DNA collection was done in buffer TE. The simplified version of the 
protocol is presented in Figure 19. 
 
Figure 19 - Schematic representation of the strategy used to purify DNA from 
bacterial maxiculture (adapted from HiSpeed Plasmid Midi Kit QIAGEN handbook). 
 
2.2.1.7. DNA quantification 
 
The DNA quantification was done with nanodrop according to the manufacture good 
practices.  
 
Bacterial pellet 
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2.2.1.8. DNA gel extraction  
 
For DNA gel extraction, after cutting the DNA band of interest from the agarose gel with 
a clean blade the QIAEX II Gel Extraction Kit from QIAGEN was used. The protocol used is 
the same described above and schematized in Figure 17 with an incubation of 10 minutes at 50ºC 
(solubilise of agarose) preceding the first step and an additional wash with buffer QX1 (to 
remove traces of agarose) after the first centrifugation.  
 
2.2.1.9. Genomic DNA extraction 
 
To extract genomic DNA from HUVECs and iPSCs the Flexigene DNA kit from 
QIAGEN was used. The number of cells never exceeded 2x106 per reaction. After collecting the 
cells, the cells were spined down for 5 minutes at 1200rpm. The cell pellets were ressuspended 
in 300µL of buffer FG1 (lysis buffer) and 300µL of buffer FG2 (denaturation buffer) with 
QIAGEN protease (3µL per 300µL of buffer FG2) was added after homogeneous ressuspension. 
The solution was mixed by inverting the tube 3 times and 10 minutes incubation at 65ºC was 
done. After this incubation period, 600µL of isopropanol were used to generate DNA visible 
precipitates. The DNA precipitates was then centrifuged at 13.000rpm for 3 minutes and washed 
with 70% ethanol. The clean DNA precipitate was then air dried, ressuspended in buffer FG3 
(hydration buffer) and dissolved during 30 minute at 65ºC.(Figure 20) 
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Figure 20 - Schematic representation of the strategy used to purify DNA from 
bacterial maxiculture (adapted from Flexigene DNA kit QIAGEN handbook). 
 
2.2.2. Viral work 
 
Lentiviruses are vectors based on the life cycle of retroviruses, as HIV, and for safety 
reasons a great majority of the viral proteins are not present (as tat protein).  
In this work HIV-1 based pantropic lentivirus and a third generation packaging were 
used. In this type of packaging systems the cis-acting viral elements are inserted within the 
construct of interest and the transacting elements are within three individual packaging 
plasmids. This lentiviral packaging system comprises a plasmid for gag, that codes for the virion 
main structural proteins and pol, coding for the retrovirus-specific enzymes (pMDLg/pRRE). In 
a separate packaging plasmid there is the rev element, which is responsible for expression of a 
post-transcriptional regulator necessary for efficient gag and pol expression (pRSVrev). The 
third packaging plasmid is responsible for the formation of viral envelope (pMD2-G/VSV-G) 
(Spirin, Vilgelm & Prassolov, 2008; Dull et al., 1998). 
 
The lentiviral genome consists of two identical single stranded RNAs, which are 
packaged in a virus capsid. The capsid includes the structural proteins encoded by gag and the 
products of pol, virus-specific reverse transcriptase, protease, and integrase (Figure 21). 
 
Cellular pellet 
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Figure 21 - Scheme of a virus particle (Dull et al., 1998) 
 
2.2.2.1.  Viral packaging 
 
To achieve the viral packaging of the generated construct (named PLenti-VEpr-Cherry), 
pMDLg/pRRE, pRSVrev and pMD2-G (VSV-G) packaging plasmids were used (Figure 22). 
The viral packaging was performed in 293T (ATCC) with the respective amounts of 
transfection agent (FuGene - Roche) and plasmids in the Table IV.The FuGene was mixed with 
DMEM without serum and incubated at room temperature for 10 minutes. After the incubation 
period plasmids were added and maintained at room temperature for 40 minutes. Lastly, this 
mixture was added to a 70% 293T culture flask (T75). The 293T medium was changed by fresh 
293T medium after 16 h of incubation (at 37ºC). 
Table IV – Conditions used to perform the viral packaging. 
Component Amount (per T75 flask) 
FuGene 23,1 µL 
pMDLg/pRRE 1,3 µg 
pRSVrev 1,3 µg 
pMD2-G (VSV-G) 1,3 µg 
PLenti-VEpr-Cherry 1,95 µg 
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2.2.2.2. Concentrating the virus 
 
Three days after the transfection of the 293T described in Table IV the viral supernatants 
were collected into 50mL tubes and spin down at 1500rpm during 5 minutes to pellet the cellular 
debris. After this centrifugation the supernatants were filtered (0,4µM filter – Appleton Woods) 
into Oak Ridge centrifuge tubes (Nalgene) and centrifuged at 22000rpm for 4 hours. The pellets 
were then ressuspended in 200µL of PBS and stored at -80ºC. 
 
Figure 22 – Schematic representation of the viral packaging strategy (adapted from 
http://www.invivogen.com/docs/Insight_201004.pdf) 
 
2.2.2.3. Viral titration  
 
In order to titrate the virus, HUVECs were infected with different amounts of viral 
particles and 5 days after the infection the fluorescent signal in the HUVECs was quantified by 
fluorescent cell cytometry (Gallios -Beckman Coulter). 
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2.2.2.4. Viral infection 
 
The viral infections (Figure 23) were performed either in suspension (for iPS) or with 
cells in adherent culture (for iPS and HUVECs). The incubation with the viral particles was 
done in normal medium used to grow the specific type of cell and during approximately 16-18 
hours. After this period the cells were rinsed 1 time with PBS and the culture medium was 
changed with new medium. 
 
Figure 23 – Schematic representation of the viral infection strategy (adapted from 
http://www.invivogen.com/docs/Insight_201004.pdf). 
 
  
After infecting the cells (HUVECs and iPSCs) the viral integration was accessed by 
polymerase chain reaction (PCR) with specific primers (as showed in Table V) to the mCherry 
fragment. After adjusting the PCR conditions the amplification of the fragment of interest was 
observed (Figure 60). 
 53
Table V – Conditions used to perform the PCR. 
 Amount (µL) per PCR reaction 
Hot start Taq 0,5 
PCR buffer 10x 1,5 
dNTPs 1,2 
Primers (forward and reverse) 3 
H2O 8,8 
DNA 1 (dilution factor 1:10) 
PCR cycle conditions  
1 hold  95ºC 15 minutes  
30 cycles  94ºC 20 seconds + 62,5ºC 20 seconds + 72ºC 20 seconds 
2 holds  72,0ºC 
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3. Results and discussion 
 
3.1. Cell culture 
 
3.1.1. Characterization of iPSCs 
 
After establishing a feeder free iPS culture with selection of CD326+ cells and culture in 
matrigel with conditioned medium, the iPSCs tend to acquire a different morphology (Figure 24) 
compared with the iPSCs cultured with MEFs (Figure 25). The MEFs secrete important growth 
factors that maintain the iPSCs in a pluripotent state and when plated without MEFs the iPSCs 
present a different morphology already described and must be cultured with iPS medium 
conditioned by MEFs (Wagner & Welch, 2010). 
 
Figure 24- iPSCs cultured in MEFs. 
 
 
Figure 25- iPSCs cultured in matrigel in feeder-free conditions. 
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The characterization of iPSCs revealed that these cells express pluripotency markers 
(ref) like TRA1-60 (Figure 26), SSEA-4 (Figure 27), and TRA1-80 (Figure 28) and do not express 
endothelial markers like CD31 and vascular endothelial cadherin. 
 
  
  
Figure 26- iPSCs immunolabeling with TRA-1-60. 
 
 
 
 
Figure 27- iPSCs immunolabeling with SSEA-4 
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Figure 28- iPSCs immunolabeling with TRA-1-80. 
 
3.1.1.1.  Nanoparticle internalization by iPSCs 
 
In terms of nanoparticle internalization these cells are able to internalize either organic 
nanoparticles (with positive - NP+ or negative - NP- surfaces) that are adhered to different 
substrates or nanoparticles in suspension. These nanoparticles can be modified with different 
cargo, therefore these nanocarriers can also be used in future work to deliver differentiation 
factors to iPSCs at different time points of the differentiation process. These internalization tests 
were done with several substrates to study both the adhesion and proliferation (Table VI) of the 
cells but also to try to assess the “tug-of-war” established between the cells and the different 
substrates for nanoparticle capture. A right balance of electrostatic interactions between 
nanoparticles and the substrate has to be found that enables the internalization of these 
nanoparticles by the cells. In the future these platforms could be tested to differentiate iPSCs 
into endothelial cells, combining the ability to promote cell adhesion, nanoparticle adhesion and 
incorporation of endothelial driving factors (hyaluronic acid and others.)  
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The preliminary results regarding these experiments show really different results 
regarding cell adhesion and proliferation and the platforms that provide a better result within 
these parameters are highlighted in Table VI. Although these results can not be used to generate 
statistical significant data there are some trends that seem to be patent. The presence of 
hyaluronic acid in the surface that contacts with cells seems to decrease the adhesion of cells 
(Table VI, Figure 31 and Figure 33). And in some way the nanoparticles seem to in some cases 
increase the adhesion of cells but in other situations appear to have the opposite effect (Table 
VI). 
 
 
   
  
Figure 29 - iPSCs immunolabeling with SSEA-4 (red labelling), and NP+ pattern 
(green fluorescence) plated in a matrigel with NP+ adhered substrate. 
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Table VI – Number of cells per substrate after different substrate 
 
 The figures presented (Figure 29, Figure 30, Figure 31, Figure 32, Figure 33) show that 
iPSCs are able to internalize the two sets of nanoparticles associated with the different 
Conditions 1 h 2 h 4 h 6 h 24 h 48 h 72 h 144 h 168 h 
coverslip 2 2 3 2 2 0 0 0 0 
coverslip+NP+ 0 1 2 2 0 0 0 0 0 
coverslip+NP- 2 3 3 4 0 0 0 0 0 
coverslip+PS+NP- 1 1 1 1 3 0 0 3 0 
coverslip+PS+HA 0 2 1 1 0 0 0 0 0 
coverslip+HA 0 1 1 1 1 0 0 1 0 
coverslip+PS+HA+NP+ 0 2 1 1 0 0 0 0 0 
coverslip+HA+NP+ 0 0 0 0 0 0 0 0 0 
coverslip+matrigel 6 5 5 7 8 10 11 15 29 
coverslip+matrigel+NP+ 4 4 8 6 8 2 1 0 0 
coverslip+matrigel+NP- 2 3 5 5 6 4 8 15 23 
Poly-Dopa 7 8 7 6 6 5 22 30 104 
Poly-Dopa+NP+ 4 4 6 5 4 0 0 0 0 
Poly-Dopa+NP- 5 6 6 10 13 10 12 83 187 
Poly-Dopa+HA+NP-PS 0 0 0 0 0 0 0 0 0 
Poly-Dopa+HA 0 3 3 5 6 1 0 0 0 
Gelatin1 4 8 5 7 4 3 4 2 2 
Gelatin1+PS 2 8 7 5 2 0 0 0 0 
Gelatin1+PS+NP-PS 5 8 9 4 7 1 1 1 0 
Gelatin1+PS+HÁ 0 0 0 0 0 0 0 0 0 
Gelatin1+PS+HÁ+NP-PS 0 0 0 0 0 0 0 0 0 
Gelatin2 4 4 4 4 4 6 15 79 171 
Gelatin2+HA 6 8 6 10 8 5 17 24 54 
Gelatin2+HA+NP-PS 4 3 5 5 4 4 9 65 75 
Gelatin2 HA inc 3 5 6 5 5 4 7 11 0 
Gelatin2+HA inc+NP+ 2 6 4 7 1 0 2 7 7 
Matri HA inc 7 7 11 10 12 35 53 143 198 
Matri HA inc +NP+ 2 3 4 6 9 10 14 92 179 
Gelatin3 7 10 9 11 6 8 17 41 62 
Gelatin3+HA 5 6 10 10 11 13 10 15 128 
Gelatin3+HA+NP-PS 4 6 7 6 6 4 3 11 29 
Gelatin3 HA inc 9 8 7 6 11 14 12 24 20 
Gelatin3 HA inc+NP-PS 3 8 7 7 4 12 10 57 102 
Poly-Dopa+PS+HA 0 3 2 2 1 0 0 0 0 
Poly-Dopa+PS+HA+NP+ 0 5 12 15 16 12 11 131 176 
Poly-Dopa+PS 4 6 5 3 2 2 0 0 0 
Poly-Dopa+PS+NP- 5 6 11 10 9 20 36 102 213 
Methylc+PS+NP- 1 3 3 3 1 1 1 1 0 
Methylc+PS 1 2 3 3 1 0 0 0 0 
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substrates. Future work will be performed to further clarify the interaction of the different 
nanoparticles with the different substrates and to generate quantitative and statistical significant 
data. 
  
 
   
   
Figure 30 - iPSCs cultured in a matrigel with HA incorporated substrate with adhered 
NP+; NP+  pattern (green fluorescence); red labelling (imunostaining SSEA-4). 
 
 
Figure 31 - iPSCs cultured in Poly-dopamine, PS, HA, NP+substrate; NP+  pattern 
(green fluorescence). 
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Figure 32 - iPSCs cultured in Poly-dopamine NP+ (green fluorescence left image) 
substrate ; Poly-dopamine NP- (green fluorescence left image)substrate. 
 
   
   
Figure 33 - iPSCs cultured in Gelatine 2 and HA substrate with NP+ (green 
fluorescence left image) 
 
3.1.2. Characterization of HUVECs 
 
HUVECs showed regular expression of endothelial markers such as CD31 and VE-
cadherin (Figure 34). 
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Figure 34- Imunolabeling of HUVECs with CD31 (white labelling) and VE-cadherin (green 
labelling) 
 
3.2. Cloning experiments 
 
3.2.1.  Generation of the VE-cadherin promoter cherry lentiviral vector 
 
In order to obtain the fragments of interest from the VEpr-GFP and mCherry clones 
illustrated on Figure 10 a restriction strategy that included HindIII and BamHI restriction 
enzymes was used. After transformation of competent cells, DNA amount was quantified (Table 
VII) in each clone and digestions were performed as briefly described below. 
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Table VII – DNA amount correspondent to each clone used 
Vector/clone DNA amount (ng/µL) 
VEpr-GFP 444,2 
Pcr-mCherry 576,3 
PLenti6V5 280 
 
 
 
The digestion of the 2 clones with Hind III was done during according to Table VIII. 
 
Table VIII – Conditions used for HindIII digestion of VEpr-GFP and Pcr mCherry 
clones 
Vector/clone Water (µL) DNA (µL) NEB buffer 2  
10x (µL) 
HindIII (µL) 
VEpr-GFP 
(insert) 
77,74 11,26 10 1 
Pcr-mCherry 
(vector1) 
80,23 8,68 10 1 
 
Figure 35 shows the digestion products resulting from the digestion of HindIII. To avoid 
alteration of BamHI activity in Hind III buffer (NEB buffer 2 ), after HindIII digestion the DNA 
products were purified (QIAEX II kit from QIAGEM) and then the BamHI digestion was 
performed as shown in Table IX. 
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Figure 35 - HindIII digestion products. 1kb plus ladder; VEpr-GFP uncuted; VEpr-
GFP after HindIII digestion; Pcr mCherry uncuted; Pcr mCherry after HindIII 
digestion (from left side to right side lanes) 
 
Figure 36- HindIII + BamHI digestion products. 1kb plus ladder; VEpr-GFP cuted; 
Pcr mCherry cutted (from left side to right side lanes) 
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Table IX - Conditions used for BamHI digestion of VEpr-GFP and Pcr mCherry 
clones 
Vector/clone Water (µL) DNA (µL) 
after cutting 
with Hind II 
and desalted 
Bam/Sal NEB 
buffer 10x 
(µL) 
BamHI (µL) 
VEpr-GFP 49 40 10 1 
Pcr-mCherry  49 40 10 1 
 
After BamHI digestion (Figure 36) in the case of the mCherry clone a dephosphorilation 
step (with AP – calph intestitinal phosphatase NEB ) was done to avoid the re-annealing of the 
mCherry backbone. 
 
Both digestion products were then gel purified and ligated. The ligation products (Figure 
37) after transformation into competent cells did not originate any bacterial colony.  
 
 
Figure 37 - HindIII + BamHI digestion products ligation. 1kb plus ladder; Pcr mCherry 
fragment ligated the VEpr-GFP fragment; Pcr mCherry fragment ligated with no VEpr-
GFP fragment, Pcr mCherry fragment non ligated (from left side to right side lanes). 
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These results might have been due to excessive dephosphorilation of the mCherry 
backbone but also might reflect some DNA damage due to UV exposure during gel extraction. 
Therefore repetition of the digestions of the mCherry clone was done with the same enzymes but 
using a lower concentration of AP and not performing gel purification (A) (Figure 38, Figure 39, 
Figure 40, Figure 41) or without using AP and doing only gel purification of the fragments of 
interest (B) (Figure 38, Figure 39, Figure 40, Figure 41). 
 
The digestion of the mCherry clone with Hind III was done as described in Table X. 
 
Table X - Conditions used for BamHI digestion of Pcr mCherry clone 
Vector/clone Water (µL) DNA (µL) NEB buffer 2  
10x (µL) 
HindIII (µL) 
Pcr-mCherry 
(vector1) 
85,66 4,34 10 1 
 
 
Figure 38 shows the digestion products resulting from the digestion of HindIII. The same 
purification step mentioned before was done and then the BamHI digestion was performed as 
shown in Table XI. 
 
Figure 38- HindIII digestion products. 1kb plus ladder; Pcr mCherry uncuted; Pcr 
mCherry after HindIII digestion A; Pcr mCherry after HindIII digestion B (from left 
side to right side lanes) 
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Figure 39- HindIII purified digestion products. 1kb plus ladder; Pcr mCherry uncuted; Pcr 
mCherry after HindIII digestion A; Pcr mCherry after HindIII digestion B (from left side to right 
side lanes) 
 
 
 
 
 
Table XI - Conditions used for BamHI digestion of VEpr-GFP and Pcr mCherry 
clone 
Vector/clone Water (µL) DNA (µL) 
after cutting 
with Hind II 
and desalted 
Bam/Sal NEB 
buffer 10x 
(µL) 
BamHI (µL) 
Pcr-mCherry  49 40 10 1 
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Figure 40 - HindIII + BamHI digestion products. 
Left side image: 1kb plus ladder; Pcr mCherry uncuted; Pcr mCherry cutted B (gel 
extraction); empty; 1kb plus ladder; Pcr mCherry cutted A (from left side to right side 
lanes). 
Right side image: 1kb plus ladder; Pcr mCherry uncutted; purified Pcr mCherry cuted 
A; purified Pcr mCherry cuted B (from left side to right side lanes). 
 
 
Figure 41- HindIII + BamHI digestion products ligation. 
1kb plus ladder; Pcr mCherry fragment A ligated the VEpr-GFP fragment; Pcr mCherry 
fragment A ligated with no VEpr-GFP fragment, Pcr mCherry fragment A  non ligated 
(from left side to right side lanes). 
1kb plus ladder; Pcr mCherry fragment B ligated the VEpr-GFP fragment; Pcr mCherry 
fragment B ligated with no VEpr-GFP fragment, Pcr mCherry fragment B non ligated 
(from left side to right side lanes). 
 
 
Bacterial colonies were only obtained from the transformation of the ligation products 
where we did not perform gel purification of the mCherry backbone (A). Unfortunately all the 
colonies were negative for the presence of the VEpr-GFP fragment of interest (Figure 42). The 
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presence of the fragment of interest from the VEpr-GFP clone was checked by enzymatic 
digestion of the DNA from the different colonies with NotI and HindIII (Figure 11). 
 
 
 
Figure 42-Restriction digestion with Not I and Hind III of the different clones from 
VEpr-mCherry A ligation to confirm the presence of VEpr. 
 
In order to overcome these problems a digestion of the mCherry clone was performed 
with HindIII and BamHI (Table XII, Table XIII and Figure 43, Figure 44 and Figure 45) followed 
by dephosphorilation (with AP) and gel extraction, but this time the transformation of the 
ligation products was performed with ultra competent cells.  
 
Table XII - Conditions used for HindIII digestion of VEpr-GFP and Pcr mCherry 
clone 
Vector/clone Water (µL) DNA (µL) NEB buffer 2  
10x (µL) 
HindIII (µL) 
Pcr-mCherry 80,23 8,68 10 1 
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Figure 43 - HindIII digestion products.  
Left side image:1kb plus ladder; Pcr mCherry uncuted; Pcr mCherry after HindIII 
digestion (from left side to right side lanes). Right side image: 1kb plus ladder; 
purified Pcr mCherry after HindIII digestion (from left side to right side lanes) 
 
 
 
 
 
Table XIII - Conditions used for BamHI digestion of VEpr-GFP and Pcr mCherry clone 
Vector/clone Water (µL) DNA (µL) 
after cutting 
with Hind II 
and desalted 
Bam/Sal NEB 
buffer 10x 
(µL) 
BamHI (µL) 
Pcr-mCherry  49 40 10 1 
 
After BamHI digestion, the Pcr-mCherry clone was dephosphorilated and then gel 
purified (Figure 44). 
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Figure 44 - HindIII + BamHI digestion products. 
Left side image: 1kb plus ladder; Pcr mCherry uncuted; empty; Pcr mCherry cutted 
(gel extraction);(from left side to right side lanes). 
Right side image: 1kb plus ladder;  gel purified Pcr mCherry fragment (from left side to right 
side lanes). 
 
 
Figure 45 - HindIII + BamHI digestion products ligation. 
1kb plus ladder; Pcr mCherry fragment ligated the VEpr-GFP fragment; Pcr mCherry 
fragment  ligated with no VEpr-GFP fragment, Pcr mCherry fragment non ligated (from 
left side to right side lanes). 
 
 
With the colonies obtained from the transformation of the ligation products (Figure 45) 
bacterial minicultures were established and the purified DNA (mini spin kit QIAGEN) digested 
with NotI and Hind III. This digestion showed that eleven colonies were positive for the 
fragment of interest from the VEpr-GFP clone (Figure 46).  
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Figure 46 – Restriction digestion with Not I and Hind III of the different clones from VEpr-
mCherry ligation to confirm the presence of VEpr (arrows indicate positive clones). 
 
Some of these positive clones were selected and maxicultures were established for two 
positive clones (17 and 34) that showed a good linearization pattern after Hind III digestion 
(Figure 47). 
 
 
Figure 47 – Hind III digestion of VEpr-mCherry positive clones. 1kb plus ladder; clone 
17 uncuted; clone 17 cuted; clone 34 uncuted; clone 34 cuted; clone 11 uncuted; clone 
11 cuted; clone 24 uncuted; clone 24 cuted; clone 26 uncuted; clone 26 cuted;  clone 31 
uncuted; clone 31 cuted; clone 32 uncuted; clone 32 cuted (from left side to right side 
lanes). 
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After this step, the DNA amount within this maxicultures was analyzed and is presented 
on Table XIV. 
 
Table XIV – DNA amount of maxicultures from clones 17 and 34 
Clone DNA amount (ng/µL) 
17 17,8 
34 52,6 
 
The orientation of the fragment of interest was confirmed with a digestion presented in 
Figure 16and Figure 48. 
 
Figure 48 - Restriction digestion with HincII and PspOMI of the 34 clone from VEpr-mCherry 
ligation to confirm the orientation of VEpr. 1kb plus ladder; clone 34 uncuted; clone 34 cuted 
with PspOMI; clone 34 cuted with HincII (from left side to right side lanes). 
 
Regarding the second step of sub cloning the initial strategy was to cut the PLenti6V5 
and the VEpr-mCherry clones with ClaI plus Spume (followed by AP dephosphorilation) and 
HpaI plus Not I, respectively (Figure 13 and Figure 49). This strategy was based on the fact that 
the enzyme klenow large fragment could be used to generate a blunt end in the PLenti6v5 clone 
after cutting with ClaI and as Spume and Not I produce compatible ends we would have ligation 
of the fragments of interest. 
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A 
B 
C 
D 
Figure 49- Second cloning step (first strategy). A - 1kb plus ladder; clone 34 uncuted;; 
clone 34 cuted with HpaI; PLenti6v5 uncuted; PLenti6v5 cutted with ClaI(from left side 
to right side lanes). B - 1kb plus ladder; clone 34 uncuted; empty; clone 34 cuted with 
HpaI +  NotI (gel extraction) (from left side to right side lanes). B - 1kb plus ladder; 
PLenti6v5 uncuted; empty; PLenti6v5 cuted with ClaI + Spume (gel extraction) (from 
left side to right side lanes). C - 1kb plus ladder ; 34 cuted with HpaI +  NotI gel purified; 
PLenti6v5 cuted with ClaI + Spume gel purified 
 
Several problems arouse although the type of competent cells was changed the 
generation of bacterial colonies from transformation of different ligation products was not 
successful. This result might have been related with the blunting process with large fragment of 
klenow, because although this enzyme has lost 5’ to 3’ exonuclease activity it still has 3’ to 5’ 
exonuclease activity and might contribute to degrade the DNA of the PLenti6v5 clone. 
Therefore we ended up using another strategy with HpaI and PsPOMI to digest the PLenti6V5 
clone (Figure 14) and maintaining the restriction strategy for the VEpr-Mcherry clone and 
consequently avoiding the need to use the klenow large fragment to blunt any end because the 
enzymes used in the different clones produce compatible ends. 
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A B C 
Figure 50 - Second cloning step (final strategy). A - 1kb plus ladder; PLenti6v5 
cutted with HpaI+PsPOMI (from left side to right side lanes). B - - 1kb plus ladder; 
PLenti6v5 uncuted; empty; PLenti6v5 cutted with HpaI+PsPOMI (from left side to 
right side lanes) C - - 1kb plus ladder; gel purified PLenti6v5 cutted with 
HpaI+PsPOMI; gel purified clone 34 cutted with HpaI and NotI (from left side to 
right side lanes). 
 
 
 
 
 
 
Figure 51 – VEpr-mCherry and PLenti6v5 digestion products ligation. 
1kb plus ladder; VEpr- mCherry fragment ligated with the PLenti6v5 fragment; VEpr- mCherry 
fragment ligated with no PLenti6v5 fragment; VEpr- mCherry fragment non ligated (from left 
side to right side lanes). 
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Figure 52- VEpr-mCherry digestion to confirm the presence of the fragment of interest. 
1kb plus ladder; Pcr mCherry cutted with EcoRI; uncuted VEpr-mCherry clone (clone 
34); VEpr-mCherry clone (clone 34) cutted with Eco RI; VEpr-mCherry clone (clone 
34) cutted with Eco NI (from left side to right side lanes). 
 
With this new approach we were able to obtain one positive colony for the fragment of 
interest from VEpr-mCherry that was confirmed with a restriction digestion using EcoRI and 
EcoNI (Figure 16 and Figure 52) and posterior establishment of a respective maxiculture with 
respective amount of DNA presented in Table XV. 
 
Table XV – DNA quantification of VEpr-mCherry clone 
Clone DNA amount (ng/µL) 
VLI9 101,2 
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3.3. Viral work 
 
After performing the viral packaging as described in material and methods section viral 
titration was assessed. HUVECs were infected with different amounts of viral suspension and 5 
days after infection the percentage of red fluorescent cells was analyzed.  
 
3.3.1.  Infection of  HUVECs with the lentiviral vector for viral titration  
 
 
Figure 53- Fluorescence labelling of untransduced (blue) and transduced (red 
fluorescence) HUVECs. 
 
 
Figure 54- Transduced and blasticidin selected HUVECs 
 
The data presented here (Table XVI, Figure 53 and Figure 54) above shows that 5 days 
after the viral infection the HUVECs present red fluorescence. Cells infected with increasing 
amounts of viral concentrate 50µL of viral suspension had a 6,22% red labelled cells, with 
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100µL of viral suspension 11,59% presented red fluorescence and using 300µL of viral 
suspension 23,59% cells show integration of the viral DNA (red fluorescence).  
 
Table XVI – Fluorescent patterns of transduced HUVECs 
Viral suspension 
added (µL) 
Number of cells 
Percentage of cells Mcherry+ 
(5days after infection) 
Mean of fluorescence 
intensity 
50 65500 6,22 3,34 
100 65500 11,59 3,82 
300 65500 23,29 4,45 
 
3.3.1.1.  Blasticidin selection of HUVECs after infection with the lentiviral vector 
 
The selection with blasticidin as reported in several studies (refs), eliminates non 
resistant cells by inhibition of translational. This was observed in untransduced HUVECs where 
all the cells died after 5 days with blasticidin ( 5µg, 10µg and 25µg per ml of medium - Figure 
55) within the regular endothelial medium. Maintaining PLenti-VEpr-mCherry infected 
HUVECs (transduced) in culture during 5 days we observed by FACS (Table XVI) that the 
percentage of labelled cells tends to increase with increasing concentrations of blasticidin (Table 
XVII) but not significantly. This might be explained by the fact that the number of viral 
integrants within the HUVEC transduced population is highly heterogeneous and therefore the 
expression of mCherry will also be heterogeneous (Figure 54). Additionally, it is possible that 
some cells that are blasticidin resistant present really low levels of fluorescence due to the fact 
that mCherry is monomeric and the fluorescence intensity (50-75% of EGFP (ref)) it produces is 
sub-optimal for the settings of the cytometer available at Biocant. Another reason for the 
presence of non-fluorescent cells after blasticidin selection is the short half-life of this protein 
(15 minutes) (Shaner et al., 2004). This means that in a proliferating population of cells we will 
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always have cells that are low or non-fluorescent because there is no transcription during mitosis 
so during early G1 the cells won’t have much red fluorescence.  
Nevertheless, one of the main advantages of using mCherry is due to the fact that this 
monomeric protein has less toxic effects within the cells than other oligomeric fluorescent 
proteins (e.g. GFP) (Shaner et al., 2004).  
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Figure 55- Cell behaviour during blasticidin selection of untransduced and transduced HUVECs 
 
 
 
 
Table XVII –  Fluorescent labelling of untransduced and transduced HUVECs 
 
 
 
 The infected HUVECs selected with blasticidin present red fluorescence (resulting from 
the viral transduction) and show immunolabeling of CD31 as presented in Figure 56. 
Condition  Gated % of red (FL3) 
labelled cells 
Total % of red (FL3) labelled cells 
HUVECs untransduced 2,29 1,55 
HUVECs transduced without 
blasticidin selection 
95,57 58,08 
HUVECs transduced with 
blasticidin selection (5µg/mL) 
94,35 57,21 
HUVECs transduced with 
blasticidin selection (10µg/mL) 
95,20 60,82 
HUVECs transduced with 
blasticidin selection (25µg/mL) 
93,76 62,16 
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Figure 56 – Fluorescent labelling of transduced HUVECs, mCherry protein (red 
fluorescence); CD31 immunolabeling (green fluorescence). 
 
3.3.2. Infection of iPS cells with the lentiviral vector  
 
 
Figure 57- Fluorescence labelling of untransduced (blue) and transduced (red fluorescence) 
iPSCs. 
The data presented above (Figure 57) demonstrate that 12 days after the viral infection of 
iPSCs there is no change in the red fluorescence pattern of infected iPSCs (transduced) versus 
non transduced iPSCs.  
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3.3.2.1.  Blasticidin selection of iPS after infection with the lentiviral vector 
 
Regarding the iPS selection, in the control situations the cell death was proportional to 
the concentration of blasticidin and within 72 hours after culturing untransduced iPSCs with 
blasticidin there were no more live cells. Within the experimental situations it was noticed some 
cell death but cell proliferation was occurring normally and therefore denoting the presence of 
blasticidin resistant iPSCs (Figure 58). Nevertheless, the FACS analysis shows no alteration 
between the control situation and the infected iPSCs (Figure 59). Therefore the selection with 
blasticidin did not promote any alteration in terms of vascular endothelial-cadherin expression. 
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Figure 58- Cell behaviour during blasticidin selection of untransduced and transduced iPSCs. 
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Transduced iPSCs+20 µg of blasticidin  
Figure 59- Cell fluorescent behaviour during blasticidin selection of untransduced 
and transduced iPSCs. 
 
 
3.3.3. Genomic integration of viral work by HUVECs and iPSCs 
 
After infecting the cells (HUVECs and iPSCs) the viral integration was accessed by 
polymerase chain reaction (PCR) with specific primers (Table V) to the mCherry fragment. After 
adjusting the PCR conditions the amplification of the fragment of interest was observed (Figure 
60). 
 
Figure 60 – PCR amplification products (1,2%agarose gel). Water; HUVECs untransduced; 
HUVECs transduced; iPSCs untransduced; iPSCs transduced; 1kbplus ladder (from left side 
to right side lanes) 
 
 
3.4. On going work  
 
3.4.1.  Differentiation of VE-cadherin promoter cherry  iPS cells with and without 
blasticidin selection 
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The blasticidin selected iPSCs and also unselected iPSCs were treated according to 
different endothelial differentiation protocols, already described (Levenberg et al., 2002; 
Lagarkova et al., 2008). Unfortunately the iPSCs in culture are not yet differentiated into 
endothelial cells, they present negligible immunolabeling of CD31 and VE-cadherin.  
This demonstrate that the reporter system that is described here may have a really 
important role in the optimization of the differentiation protocols, because in addition to the low 
efficiencies obtained with the different protocols the cell type used to generate endothelial cells 
might also have a great impact in the differentiation output. Therefore, using the screening tool 
described here will permit also the monitorization of differentiation of different cell sources 
since the packaging of this virus enables the infection of every mammalian cell type (hESCs, 
iPSCs, EPCs and others). 
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Chapter 4                                                                       
      
 
 
Conclusion 
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4. Conclusion 
 
The work described here, lead to the successful generation of a molecular biology tool 
that permits the screening of endothelial differentiation. In order to achieve this purpose there is 
some on going work to generate a stable cell line of transduced (Plenti6V5-VEpr-mCherry) 
iPSCs. These cells after blasticidin selection will be sorted for pluripotency markers (CD326 
with MACS system) to ensure their pluripotency. Furthermore a clonal selection, expansion and 
differentiation will prove the integration of the viral DNA and the establishment of the desired 
iPSC cell line. Additionally this tool can also be applied to other cells and also to study 
processes like transdifferentiation (Haase et al., 2009; Graf & Enver, 2009). Therefore, this 
reporter system can be applied to a variety of cells and study their endothelial potential in 
different environmental conditions. 
The monitorization of endothelial differentiation with this tool can be adjusted to high 
throughput screening methods already described by Ng et al 2005, 2008 that have developed a 
96-well spin EB method. Additionally, Koike et al. 2007 have constructed a 96-well murine 
ESCs differentiation system and studied the effect of EB seeding density in the output of 
cardiomyocyte differentiation. Other studies have developed 384 well plate (Outten et al., 2011) 
screening platforms. Generation of biomaterial high throughput screening platforms is 
associated with micropatterned surfaces. In these platforms the effect of different polymers and 
matrices on cell differentiation and the use of different chemical components like cytokines, 
growth factors, miRNAs, siRNA can be concomitantly tested. These kinds of biomaterial 
platforms circumvent the need of either using large number of cells (miniaturized platforms) or 
interrupting the differentiation process in different time points in order to access the 
differentiation state of the cells. Therefore the screening process can be retransformed into a less 
time and resource consuming process.  
 89
Furthermore the ability of internalization of the nanoparticle and adhesion of iPSCs to 
different substrates (that may present potential endothelial induction characteristics), concerted 
with the reported system developed, might be a potent way to try to improve the differentiation 
process. In one hand the nanoparticle delivery system might be used to improve the delivery of 
differentiation factors and explore the importance of the specific time point delivery of 
differentiation factors that have major effects in the endothelial differentiation. On the other 
hand, the use of different substrates might improve the differentiation process by giving 
endothelial specific cues to the cells.  
The use of the endothelial reporter system here described will permit the screening of 
different endothelial differentiation strategies, namely the use of different nanoparticle cargo 
combination and different matrices. During this screening process when the cells present red 
fluorescence is a sign of their commitment to the endothelial differentiation pathway, since the 
promoter associated with the fluorescent protein codes for a late specific endothelial marker 
(Kita-Matsuo et al.,  2009). 
We hope that this work may contribute in the future for a better understanding of the 
vasculogenesis and the angiogenic process and their implication in prevalent diseases as cancer 
and ischemic conditions. 
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Annexe  I – DNA sequences of the clones used 
pCR -mcherry clone: 4071bp 
 
 
AGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTTGGCCGATTCATTAATGCAGCT
GGCACGACAGGTTTCCCGACTGGAAAGCGGGCAGTGAGCGCAACGCAATTAATGTG
AGTTAGCTCACTCATTAGGCACCCCAGGCTTTACACTTTATGCTTCCGGCTCGTATG
TTGTGTGGAATTGTGAGCGGATAACAATTTCACACAGGAAACAGCTATGACCATGA
TTACGCCAAGCTATTTAGGTGACACTATAGAATACTCAAGCTATGCATCAAGCTTGG
TACCGAGCTCGGATCCACTAGTAACGGCCGCCAGTGTGCTGGAATTCGCCCTTTGGC
CACAACCATGGTGAGCAAGGGCGAGGAGGATAACATGGCCATCATCAAGGAGTTC
ATGCGCTTCAAGGTGCACATGGAGGGCTCCGTGAACGGCCACGAGTTCGAGATCGA
GGGCGAGGGCGAGGGCCGCCCCTACGAGGGCACCCAGACCGCCAAGCTGAAGGTG
ACCAAGGGTGGCCCCCTGCCCTTCGCCTGGGGCATCCTGTCCCCTCAGTTCATGTAC
GGCTCCAAGGCCTACGTGAAGCACCCCGCCGACATCCCCGACTACTTGAAGCTGTC
CTTCCCCGAGGGCTTCAAGTGGGAGCGCGTGATGAACTTCGAGGACGGCGGCGTGG
TGACCGTGACCCAGGACTCCTCCCTGCAGGACGGCGAGTTCATCTACAAGGTGAAG
CTGCGCGGCACCAACTTCCCCTCCGACGGCCCCGTAATGCAGAAGAAGACCATGGG
CTGGGAGGCCTCCTCCGAGCGGATGTACCCCGAGGACGGCGCCCTGAAGGGCGAG
ATCAAGCAGAGGCTGAAGCTGAAGGACGGCGGCCACTACGACGCTGAGGTCAAGA
CCACCTACAAGGCCAAGAAGCCCGTGCAGCTGCCCGGCGCCTACAACGTCAACATC
AAGTTGGACATCACCTCCCACAACGAGGACTACACCATCGTGGAACAGTACGAACG
CGCCGAGGGCCGCCACTCCACCGGCGGCATGGACGAGCTGTACAAGTAAAGGCCC
AAGGGCGAATTCTGCAGATATCCATCACACTGGCGGCCGCTCGAGCATGCATCTAG
AGGGCCCAATTCGCCCTATAGTGAGTCGTATTACAATTCACTGGCCGTCGTTTTACA
ACGTCGTGACTGGGAAAACCCTGGCGTTACCCAACTTAATCGCCTTGCAGCACATC
CCCCTTTCGCCAGCTGGCGTAATAGCGAAGAGGCCCGCACCGATCGCCCTTCCCAA
CAGTTGCGCAGCCTGAATGGCGAATGGACGCGCCCTGTAGCGGCGCATTAAGCGCG
GCGGGTGTGGTGGTTACGCGCAGCGTGACCGCTACACTTGCCAGCGCCCTAGCGCC
CGCTCCTTTCGCTTTCTTCCCTTCCTTTCTCGCCACGTTCGCCGGCTTTCCCCGTCAA
GCTCTAAATCGGGGGCTCCCTTTAGGGTTCCGATTTAGTGCTTTACGGCACCTCGAC
CCCAAAAAACTTGATTAGGGTGATGGTTCACGTAGTGGGCCATCGCCCTGATAGAC
GGTTTTTCGCCCTTTGACGTTGGAGTCCACGTTCTTTAATAGTGGACTCTTGTTCCAA
ACTGGAACAACACTCAACCCTATCTCGGTCTATTCTTTTGATTTATAAGGGATTTTG
CCGATTTCGGCCTATTGGTTAAAAAATGAGCTGATTTAACAAAAATTTAACGCGAAT
TTTAACAAAATTCAGGGCGCAAGGGCTGCTAAAGGAAGCGGAACACGTAGAAAGC
CAGTCCGCAGAAACGGTGCTGACCCCGGATGAATGTCAGCTACTGGGCTATCTGGA
CAAGGGAAAACGCAAGCGCAAAGAGAAAGCAGGTAGCTTGCAGTGGGCTTACATG
GCGATAGCTAGACTGGGCGGTTTTATGGACAGCAAGCGAACCGGAATTGCCAGCTG
GGGCGCCCTCTGGTAAGGTTGGGAAGCCCTGCAAAGTAAACTGGATGGCTTTCTTG
CCGCCAAGGATCTGATGGCGCAGGGGATCAAGATCTGATCAAGAGACAGGATGAG
GATCGTTTCGCATGATTGAACAAGATGGATTGCACGCAGGTTCTCCGGCCGCTTGG
GTGGAGAGGCTATTCGGCTATGACTGGGCACAACAGACAATCGGCTGCTCTGATGC
CGCCGTGTTCCGGCTGTCAGCGCAGGGGCGCCCGGTTCTTTTTGTCAAGACCGACCT
GTCCGGTGCCCTGAATGAACTGCAGGACGAGGCAGCGCGGCTATCGTGGCTGGCCA
CGACGGGCGTTCCTTGCGCAGCTGTGCTCGACGTTGTCACTGAAGCGGGAAGGGAC
TGGCTGCTATTGGGCGAAGTGCCGGGGCAGGATCTCCTGTCATCCCACCTTGCTCCT
GCCGAGAAAGTATCCATCATGGCTGATGCAATGCGGCGGCTGCATACGCTTGATCC
GGCTACCTGCCCATTCGACCACCAAGCGAAACATCGCATCGAGCGAGCACGTACTC
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GGATGGAAGCCGGTCTTGTCGATCAGGATGATCTGGACGAAGAGCATCAGGGGCTC
GCGCCAGCCGAACTGTTCGCCAGGCTCAAGGCGCGCATGCCCGACGGCGAGGATCT
CGTCGTGACCCATGGCGATGCCTGCTTGCCGAATATCATGGTGGAAAATGGCCGCT
TTTCTGGATTCATCGACTGTGGCCGGCTGGGTGTGGCGGACCGCTATCAGGACATA
GCGTTGGCTACCCGTGATATTGCTGAAGAGCTTGGCGGCGAATGGGCTGACCGCTT
CCTCGTGCTTTACGGTATCGCCGCTCCCGATTCGCAGCGCATCGCCTTCTATCGCCTT
CTTGACGAGTTCTTCTGAATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTG
TCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAAC
GCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCG
AACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTC
CAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTATTGACG
CCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAG
TACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATG
CAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGA
TCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACT
CGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGA
CACCACGATGCCTGTAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAAC
TACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTT
GCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCT
GGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAA
GCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAAC
GAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCA
GACCAAGTTTACTCATATATACTTTAGATTGATTTAAAACTTCATTTTTAATTTAAAA
GGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTTAACGTGAGT
TTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATC
CTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGG
TGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAACTGGCTTCA
GCAGAGCGCAGATACCAAATACTGTTCTTCTAGTGTAGCCGTAGTTAGGCCACCAC
TTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTG
GCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTT
ACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGC
TTGGAGCGAACGACCTACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAG
CGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTC
GGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATA
GTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAG
GGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCC
TTTTGCTGGCCTTTTGCTCACATGTTCTTTCCTGCGTTATCCCCTGATTCTGTGGATA
ACCGTATTACCGCCTTTGAGTGAGCTGATACCGCTCGCCGCAGCCGAACGACCGAG
CGCAGCGAGTCAGTGAGCGAGGAAGCGGAAG 
 
 
PLenti6 ires egfp: 8274bp 
 
 
AATGTAGTCTTATGCAATACTCTTGTAGTCTTGCAACATGGTAACGATGAGTTAGCA
ACATGCCTTACAAGGAGAGAAAAAGCACCGTGCATGCCGATTGGTGGAAGTAAGG
TGGTACGATCGTGCCTTATTAGGAAGGCAACAGACGGGTCTGACATGGATTGGACG
AACCACTGAATTGCCGCATTGCAGAGATATTGTATTTAAGTGCCTAGCTCGATACAT
AAACGGGTCTCTCTGGTTAGACCAGATCTGAGCCTGGGAGCTCTCTGGCTAACTAG
GGAACCCACTGCTTAAGCCTCAATAAAGCTTGCCTTGAGTGCTTCAAGTAGTGTGTG
CCCGTCTGTTGTGTGACTCTGGTAACTAGAGATCCCTCAGACCCTTTTAGTCAGTGT
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GGAAAATCTCTAGCAGTGGCGCCCGAACAGGGACTTGAAAGCGAAAGGGAAACCA
GAGGAGCTCTCTCGACGCAGGACTCGGCTTGCTGAAGCGCGCACGGCAAGAGGCG
AGGGGCGGCGACTGGTGAGTACGCCAAAAATTTTGACTAGCGGAGGCTAGAAGGA
GAGAGATGGGTGCGAGAGCGTCAGTATTAAGCGGGGGAGAATTAGATCGCGATGG
GAAAAAATTCGGTTAAGGCCAGGGGGAAAGAAAAAATATAAATTAAAACATATAG
TATGGGCAAGCAGGGAGCTAGAACGATTCGCAGTTAATCCTGGCCTGTTAGAAACA
TCAGAAGGCTGTAGACAAATACTGGGACAGCTACAACCATCCCTTCAGACAGGATC
AGAAGAACTTAGATCATTATATAATACAGTAGCAACCCTCTATTGTGTGCATCAAA
GGATAGAGATAAAAGACACCAAGGAAGCTTTAGACAAGATAGAGGAAGAGCAAAA
CAAAAGTAAGACCACCGCACAGCAAGCGGCCGCTGATCTTCAGACCTGGAGGAGG
AGATATGAGGGACAATTGGAGAAGTGAATTATATAAATATAAAGTAGTAAAAATTG
AACCATTAGGAGTAGCACCCACCAAGGCAAAGAGAAGAGTGGTGCAGAGAGAAAA
AAGAGCAGTGGGAATAGGAGCTTTGTTCCTTGGGTTCTTGGGAGCAGCAGGAAGCA
CTATGGGCGCAGCGTCAATGACGCTGACGGTACAGGCCAGACAATTATTGTCTGGT
ATAGTGCAGCAGCAGAACAATTTGCTGAGGGCTATTGAGGCGCAACAGCATCTGTT
GCAACTCACAGTCTGGGGCATCAAGCAGCTCCAGGCAAGAATCCTGGCTGTGGAAA
GATACCTAAAGGATCAACAGCTCCTGGGGATTTGGGGTTGCTCTGGAAAACTCATT
TGCACCACTGCTGTGCCTTGGAATGCTAGTTGGAGTAATAAATCTCTGGAACAGATT
TGGAATCACACGACCTGGATGGAGTGGGACAGAGAAATTAACAATTACACAAGCTT
AATACACTCCTTAATTGAAGAATCGCAAAACCAGCAAGAAAAGAATGAACAAGAA
TTATTGGAATTAGATAAATGGGCAAGTTTGTGGAATTGGTTTAACATAACAAATTGG
CTGTGGTATATAAAATTATTCATAATGATAGTAGGAGGCTTGGTAGGTTTAAGAATA
GTTTTTGCTGTACTTTCTATAGTGAATAGAGTTAGGCAGGGATATTCACCATTATCG
TTTCAGACCCACCTCCCAACCCCGAGGGGACCCGACAGGCCCGAAGGAATAGAAG
AAGAAGGTGGAGAGAGAGACAGAGACAGATCCATTCGATTAGTGAACGGATCTCG
ACGGTATCGATAAGCTTGGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGC
CTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCA
TAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAA
ACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGAC
GTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTATGGGA
CTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGGTGATGCG
GTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTCCAA
GTCTCCACCCCATTGACGTCAATGGGAGTTTGTTTTGGCACCAAAATCAACGGGACT
TTCCAAAATGTCGTAACAACTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTA
CGGTGGGAGGTCTATATAAGCAGAGCTCGTTTAGTGAACCGTCAGATCGCCTGGAG
ACGCCATCCACGCTGTTTTGACCTCCATAGAAGACACCGACTCTAGAGGATCCACT
AGTCCAGTGTGGTGGAATTCGTTAACCTCGAGCGGGATCAATTCCGCCCCCCCCCTA
ACGTTACTGGCCGAAGCCGCTTGGAATAAGGCCGGTGTGCGTTTGTCTATATGTTAT
TTTCCACCATATTGCCGTCTTTTGGCAATGTGAGGGCCCGGAAACCTGGCCCTGTCT
TCTTGACGAGCATTCCTAGGGGTCTTTCCCCTCTCGCCAAAGGAATGCAAGGTCTGT
TGAATGTCGTGAAGGAAGCAGTTCCTCTGGAAGCTTCTTGAAGACAAACAACGTCT
GTAGCGACCCTTTGCAGGCAGCGGAACCCCCCACCTGGCGACAGGTGCCTCTGCGG
CCAAAAGCCACGTGTATAAGATACACCTGCAAAGGCGGCACAACCCCAGTGCCACG
TTGTGAGTTGGATAGTTGTGGAAAGAGTCAAATGGCTCTCCTCAAGCGTATTCAACA
AGGGGCTGAAGGATGCCCAGAAGGTACCCCATTGTATGGGATCTGATCTGGGGCCT
CGGTGCACATGCTTTACATGTGTTTAGTCGAGGTTAAAAAACGTCTAGGCCCCCCGA
ACCACGGGGACGTGGTTTTCCTTTGAAAAACACGATAATACCATGGTGAGCAAGGG
CGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAA
ACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAA
GCTGACCCTGAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCT
CGTGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGA
 102
AGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACC
ATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGG
CGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGC
AACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAACGTCTATATCAT
GGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATC
GAGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCCATCGGCG
ACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCACCCAGTCCGCCCTGAGC
AAAGACCCCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGC
CGGGATCACTCTCGGCATGGACGAGCTGTACAAGTAAAGCGGCCGCGACTCTAGAG
TCGAGTCTAGAGGGCCCGCGGTTCGAAGGTAAGCCTATCCCTAACCCTCTCCTCGGT
CTCGATTCTACGCGTACCGGTTAGTAATGAGTTTGGAATTAATTCTGTGGAATGTGT
GTCAGTTAGGGTGTGGAAAGTCCCCAGGCTCCCCAGGCAGGCAGAAGTATGCAAAG
CATGCATCTCAATTAGTCAGCAACCAGGTGTGGAAAGTCCCCAGGCTCCCCAGCAG
GCAGAAGTATGCAAAGCATGCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCTA
ACTCCGCCCATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGC
TGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCTGCCTCTGAGCTATTCC
AGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAAAGCTCCCGGGA
GCTTGTATATCCATTTTCGGATCTGATCAGCACGTGTTGACAATTAATCATCGGCAT
AGTATATCGGCATAGTATAATACGACAAGGTGAGGAACTAAACCATGGCCAAGCCT
TTGTCTCAAGAAGAATCCACCCTCATTGAAAGAGCAACGGCTACAATCAACAGCAT
CCCCATCTCTGAAGACTACAGCGTCGCCAGCGCAGCTCTCTCTAGCGACGGCCGCA
TCTTCACTGGTGTCAATGTATATCATTTTACTGGGGGACCTTGTGCAGAACTCGTGG
TGCTGGGCACTGCTGCTGCTGCGGCAGCTGGCAACCTGACTTGTATCGTCGCGATCG
GAAATGAGAACAGGGGCATCTTGAGCCCCTGCGGACGGTGCCGACAGGTGCTTCTC
GATCTGCATCCTGGGATCAAAGCCATAGTGAAGGACAGTGATGGACAGCCGACGGC
AGTTGGGATTCGTGAATTGCTGCCCTCTGGTTATGTGTGGGAGGGCTAAGCACAATT
CGAGCTCGGTACCTTTAAGACCAATGACTTACAAGGCAGCTGTAGATCTTAGCCAC
TTTTTAAAAGAAAAGGGGGGACTGGAAGGGCTAATTCACTCCCAACGAAGACAAG
ATCTGCTTTTTGCTTGTACTGGGTCTCTCTGGTTAGACCAGATCTGAGCCTGGGAGC
TCTCTGGCTAACTAGGGAACCCACTGCTTAAGCCTCAATAAAGCTTGCCTTGAGTGC
TTCAAGTAGTGTGTGCCCGTCTGTTGTGTGACTCTGGTAACTAGAGATCCCTCAGAC
CCTTTTAGTCAGTGTGGAAAATCTCTAGCAGTAGTAGTTCATGTCATCTTATTATTCA
GTATTTATAACTTGCAAAGAAATGAATATCAGAGAGTGAGAGGAACTTGTTTATTG
CAGCTTATAATGGTTACAAATAAAGCAATAGCATCACAAATTTCACAAATAAAGCA
TTTTTTTCACTGCATTCTAGTTGTGGTTTGTCCAAACTCATCAATGTATCTTATCATG
TCTGGCTCTAGCTATCCCGCCCCTAACTCCGCCCATCCCGCCCCTAACTCCGCCCAG
TTCCGCCCATTCTCCGCCCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAG
GCCGCCTCGGCCTCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTA
GGGACGTACCCAATTCGCCCTATAGTGAGTCGTATTACGCGCGCTCACTGGCCGTCG
TTTTACAACGTCGTGACTGGGAAAACCCTGGCGTTACCCAACTTAATCGCCTTGCAG
CACATCCCCCTTTCGCCAGCTGGCGTAATAGCGAAGAGGCCCGCACCGATCGCCCT
TCCCAACAGTTGCGCAGCCTGAATGGCGAATGGGACGCGCCCTGTAGCGGCGCATT
AAGCGCGGCGGGTGTGGTGGTTACGCGCAGCGTGACCGCTACACTTGCCAGCGCCC
TAGCGCCCGCTCCTTTCGCTTTCTTCCCTTCCTTTCTCGCCACGTTCGCCGGCTTTCC
CCGTCAAGCTCTAAATCGGGGGCTCCCTTTAGGGTTCCGATTTAGTGCTTTACGGCA
CCTCGACCCCAAAAAACTTGATTAGGGTGATGGTTCACGTAGTGGGCCATCGCCCT
GATAGACGGTTTTTCGCCCTTTGACGTTGGAGTCCACGTTCTTTAATAGTGGACTCTT
GTTCCAAACTGGAACAACACTCAACCCTATCTCGGTCTATTCTTTTGATTTATAAGG
GATTTTGCCGATTTCGGCCTATTGGTTAAAAAATGAGCTGATTTAACAAAAATTTAA
CGCGAATTTTAACAAAATATTAACGCTTACAATTTAGGTGGCACTTTTCGGGGAAAT
GTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCA
 103
TGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGT
ATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTT
TGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCAC
GAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGC
CCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTA
TTATCCCGTATTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAG
AATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGAC
AGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACT
TACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATG
GGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACC
AAACGACGAGCGTGACACCACGATGCCTGTAGCAATGGCAACAACGTTGCGCAAA
CTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATG
GAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTT
ATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACT
GGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGG
CAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAG
CATTGGTAACTGTCAGACCAAGTTTACTCATATATACTTTAGATTGATTTAAAACTT
CATTTTTAATTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAA
ATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAA
AGGATCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAA
ACCACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCC
GAAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTTCTTCTAGTGTAGC
CGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGC
TAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGG
ACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTC
GTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTACAGC
GTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCC
GGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAAC
GCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTT
TGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGCCTTT
TTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACATGTTCTTTCCTGCGTTATCCC
CTGATTCTGTGGATAACCGTATTACCGCCTTTGAGTGAGCTGATACCGCTCGCCGCA
GCCGAACGACCGAGCGCAGCGAGTCAGTGAGCGAGGAAGCGGAAGAGCGCCCAAT
ACGCAAACCGCCTCTCCCCGCGCGTTGGCCGATTCATTAATGCAGCTGGCACGACA
GGTTTCCCGACTGGAAAGCGGGCAGTGAGCGCAACGCAATTAATGTGAGTTAGCTC
ACTCATTAGGCACCCCAGGCTTTACACTTTATGCTTCCGGCTCGTATGTTGTGTGGA
ATTGTGAGCGGATAACAATTTCACACAGGAAACAGCTATGACCATGATTACGCCAA
GCGCGCAATTAACCCTCACTAAAGGGAACAAAAGCTGGAGCTGCAAGCTT 
 
 
 
 
 
VEpr-GFP construct: 8712bp 
CAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAA
TACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAAT
ATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTT
 104
TTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAG
ATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGC
GGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTT
AAAGTTCTGCTATGTGGCGCGGTATTATCCCGTATTGACGCCGGGCAAGAGCAACT
CGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGA
AAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCA
TGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAG
CTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAA
CCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGTAGC
AATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCG
GCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCT
CGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGT
CTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTA
TCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGA
GATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCATATAT
ACTTTAGATTGATTTAAAACTTCATTTTTAATTTAAAAGGATCTAGGTGAAGATCCT
TTTTGATAATCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTC
AGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTTCTGCGCGTAAT
CTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGATC
AAGAGCTACCAACTCTTTTTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGATACCA
AATACTGTCCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCA
CCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGAT
AAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCG
GTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACA
CCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGG
AGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGA
GGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACC
TCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAA
AACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCAC
ATGTTCTTTCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTACCGCCTTTGAGT
GAGCTGATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGCGAGTCAGTGAGCGA
GGAAGCGGAAGAGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTTGGCCGATTC
ATTAATGCAGCTGGCACGACAGGTTTCCCGACTGGAAAGCGGGCAGTGAGCGCAAC
GCAATTAATGTGAGTTAGCTCACTCATTAGGCACCCCAGGCTTTACACTTTATGCTT
CCGGCTCGTATGTTGTGTGGAATTGTGAGCGGATAACAATTTCACACAGGAAACAG
CTATGACCATGATTACGCCAAGCGCGCAATTAACCCTCACTAAAGGGAACAAAAGC
TGGAGCTGCAAGCTTGGCCATTGCATACGTTGTATCCATATCATAATATGTACATTT
ATATTGGCTCATGTCCAACATTACCGCCATGTTGACATTGATTATTGACTAGTTATT
AATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCGCGTTA
CATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTG
ACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGT
CAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCA
TATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATT
ATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTAG
TCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATAGC
GGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTGACGTCAATGGGAGTTTGT
TTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAACAACTCCGCCCCATTG
ACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTCGTTT
AGTGAACCGGGGTCTCTCTGGTTAGACCAGATCTGAGCCTGGGAGCTCTCTGGCTA
ACTAGGGAACCCACTGCTTAAGCCTCAATAAAGCTTGCCTTGAGTGCTTCAAGTAGT
GTGTGCCCGTCTGTTGTGTGACTCTGGTAACTAGAGATCCCTCAGACCCTTTTAGTC
 105
AGTGTGGAAAATCTCTAGCAGTGGCGCCCGAACAGGGACCTGAAAGCGAAAGGGA
AACCAGAGCTCTCTCGACGCAGGACTCGGCTTGCTGAAGCGCGCACGGCAAGAGGC
GAGGGGCGGCGACTGGTGAGTACGCCAAAAATTTTGACTAGCGGAGGCTAGAAGG
AGAGAGATGGGTGCGAGAGCGTCAGTATTAAGCGGGGGAGAATTAGATCGCGATG
GGAAAAAATTCGGTTAAGGCCAGGGGGAAAGAAAAAATATAAATTAAAACATATA
GTATGGGCAAGCAGGGAGCTAGAACGATTCGCAGTTAATCCTGGCCTGTTAGAAAC
ATCAGAAGGCTGTAGACAAATACTGGGACAGCTACAACCATCCCTTCAGACAGGAT
CAGAAGAACTTAGATCATTATATAATACAGTAGCAACCCTCTATTGTGTGCATCAA
AGGATAGAGATAAAAGACACCAAGGAAGCTTTAGACAAGATAGAGGAAGAGCAAA
ACAAAAGTAAGACCACCGCACAGCAAGCGGCCGCTGATCTTCAGACCTGGAGGAG
GAGATATGAGGGACAATTGGAGAAGTGAATTATATAAATATAAAGTAGTAAAAATT
GAACCATTAGGAGTAGCACCCACCAAGGCAAAGAGAAGAGTGGTGCAGAGAGAAA
AAAGAGCAGTGGGAATAGGAGCTTTGTTCCTTGGGTTCTTGGGAGCAGCAGGAAGC
ACTATGGGCGCAGCCTCAATGACGCTGACGGTACAGGCCAGACAATTATTGTCTGG
TATAGTGCAGCAGCAGAACAATTTGCTGAGGGCTATTGAGGCGCAACAGCATCTGT
TGCAACTCACAGTCTGGGGCATCAAGCAGCTCCAGGCAAGAATCCTGGCTGTGGAA
AGATACCTAAAGGATCAACAGCTCCTGGGGATTTGGGGTTGCTCTGGAAAACTCAT
TTGCACCACTGCTGTGCCTTGGAATGCTAGTTGGAGTAATAAATCTCTGGAACAGAT
TTGGAATCACACGACCTGGATGGAGTGGGACAGAGAAATTAACAATTACACAAGCT
TAATACACTCCTTAATTGAAGAATCGCAAAACCAGCAAGAAAAGAATGAACAAGA
ATTATTGGAATTAGATAAATGGGCAAGTTTGTGGAATTGGTTTAACATAACAAATTG
GCTGTGGTATATAAAATTATTCATAATGATAGTAGGAGGCTTGGTAGGTTTAAGAAT
AGTTTTTGCTGTACTTTCTATAGTGAATAGAGTTAGGCAGGGATATTCACCATTATC
GTTTCAGACCCACCTCCCAACCCCGAGGGGACCCGACAGGCCCGAAGGAATAGAA
GAAGAAGGTGGAGAGAGAGACAGAGACAGATCCATTCGATTAGTGAACGGATCTC
GACGGTATCGGTTAACTTTTAAAAGAAAAGGGGGGATTGGGGGGTACAGTGCAGG
GGAAAGAATAGTAGACATAATAGCAACAGACATACAAACTAAAGAATTACAAAAA
CAAATTACAAAAATTCAAAATTTTATCGATGCTCATCCATGCCCATGGCCTCAGATG
CCAGCCATAAGCTGTTGGGTTCCAAACCTCGACTCCAGGCTGGACTCACCCCTGTCT
CCCCCACCAGCCTGACACCTCCACCTGGGTATCTAACGAGCATCTCAAACTCAACCT
GCCTGAGACAGAGGAATCACTATCCCCTCCTCCTCCAAAAATATCCTTCCATCACAC
TCCCCATCTTGTGCTCTGATTTACTAAACGGCCCTGGGCCCTCTCTTTCTCAGGGTCT
CTGCTTGCCCAGCTATATAATAAAACAAGTTTGGGACTTCCCAACCATTCACCCATG
GAAAAACAGAAGCAACTCTTCAAAGGACAGATTCCCAGGATCTGCCCTGGGAGATT
CCAAATCAGTTGATCTGGGGTGAGCCCAGTCCTCTGTAGTTTTTAGAAGCTCCTCCT
ATGTCTCTCCTGGTCAGCAGAATCTTGGCCCCTCCCTTCCCCCCAGCCTCTTGGTTCT
TCTGGGCTCTGATCCAGCCTCAGCGTCACTGTCTTCCACGCCCCTCTTTGATTCTCGT
TTATGTCAAAAGCCTTGTGAGGATGAGGCTGTGATTATCCCCATTTTACAGATGAGG
AAACTGTGGCTCCAGGATGACACAACTGGCCAGAGGTCACATCAGAAGCAGAGCT
GGGTCACTTGACTCCACCCAATATCCCTAAATGCAAACATCCCCTACAGACCGAGG
CTGGCACCTTAGAGCTGGAGTCCATGCCCGCTCTGACCAGGAGAAGCCAACCTGGT
CCTCCAGAGCCAAGAGCTTCTGTCCCTTTCCCATCTCCTGAAGCCTCCCTGTCACCTT
TAAAGTCCATTCCCACAAAGACATCATGGGATCACCACAGAAAATCAAGCTCTGGG
GCTAGGCTGACCCCAGCTAGATTTTTGGCTCTTTTATACCCCAGCTGGGTGGACAAG
CACCTTAAACCCGCTGAGCCTCAGCTTCCCGGGCTATAAAATGGGGGTGATGACAC
CTGCCTGTAGCATTCCAAGGAGGGTTAAATGTGATGCTGCAGCCAAGGGTCCCCAC
AGCCAGGCTCTTTGCAGGTGCTGGGTTCAGAGTCCCAGAGCTGAGGCCGGGAGTAG
GGGTTCAAGTGGGGTGCCCCAGGCAGGGTCCAGTGCCAGCCCTCTGTGGAGACAGC
CATCCGGGGCCGAGGCAGCCGCCCACCGCAGGGCCTGCCTATCTGCAGCCAGCCCA
GCCCTCACAAAGGAACAATAACAGGAAACCATCCCAGGGGGAAGTGGGCCAGGGC
CAGCTGGAAAACCTGAAGGGGAGGCAGCCAGGCCTCCCTCGCCAGCGGGGTGTGG
 106
CTCCCCTCCAAAGACGGTCGGCTGACAGGCTCCACAGAGCTCCACTCACGCTCAGC
CCTGGACGGACAGGCAGTCCAACGGAACAGAAACATCCCTCACCCACAGGCACGG
GATCCACCGGTCGCCACCATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGT
GCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCG
GCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACC
ACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTACGGCGT
GCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCG
CCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGACGGCAAC
TACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGA
GCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAG
TACAACTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCAT
CAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCG
ACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAAC
CACTACCTGAGCACCCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCA
CATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACGAGC
TGTACAAGTAAAGCGGCCGCGTCGACAATCAACCTCTGGATTACAAAATTTGTGAA
AGATTGACTGGTATTCTTAACTATGTTGCTCCTTTTACGCTATGTGGATACGCTGCTT
TAATGCCTTTGTATCATGCTATTGCTTCCCGTATGGCTTTCATTTTCTCCTCCTTGTAT
AAATCCTGGTTGCTGTCTCTTTATGAGGAGTTGTGGCCCGTTGTCAGGCAACGTGGC
GTGGTGTGCACTGTGTTTGCTGACGCAACCCCCACTGGTTGGGGCATTGCCACCACC
TGTCAGCTCCTTTCCGGGACTTTCGCTTTCCCCCTCCCTATTGCCACGGCGGAACTCA
TCGCCGCCTGCCTTGCCCGCTGCTGGACAGGGGCTCGGCTGTTGGGCACTGACAATT
CCGTGGTGTTGTCGGGGAAGCTGACGTCCTTTCCATGGCTGCTCGCCTGTGTTGCCA
CCTGGATTCTGCGCGGGACGTCCTTCTGCTACGTCCCTTCGGCCCTCAATCCAGCGG
ACCTTCCTTCCCGCGGCCTGCTGCCGGCTCTGCGGCCTCTTCCGCGTCTTCGCCTTCG
CCCTCAGACGAGTCGGATCTCCCTTTGGGCCGCCTCCCCGCCTGGAATTCGAGCTCG
GTACCTTTAAGACCAATGACTTACAAGGCAGCTGTAGATCTTAGCCACTTTTTAAAA
GAAAAGGGGGGACTGGAAGGGCTAATTCACTCCCAACGAAGACAAGATCTGCTTTT
TGCTTGTACTGGGTCTCTCTGGTTAGACCAGATCTGAGCCTGGGAGCTCTCTGGCTA
ACTAGGGAACCCACTGCTTAAGCCTCAATAAAGCTTGCCTTGAGTGCTTCAAGTAGT
GTGTGCCCGTCTGTTGTGTGACTCTGGTAACTAGAGATCCCTCAGACCCTTTTAGTC
AGTGTGGAAAATCTCTAGCAGTAGTAGTTCATGTCATCTTATTATTCAGTATTTATA
ACTTGCAAAGAAATGAATATCAGAGAGTGAGAGGAACTTGTTTATTGCAGCTTATA
ATGGTTACAAATAAAGCAATAGCATCACAAATTTCACAAATAAAGCATTTTTTTCAC
TGCATTCTAGTTGTGGTTTGTCCAAACTCATCAATGTATCTTATCATGTCTGGCTCTA
GCTATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGACTA
ATTTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCGGCCTCTGAGCTATTCCAGAAG
TAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCGTCGAGACGTACCCAATTCGC
CCTATAGTGAGTCGTATTACGCGCGCTCACTGGCCGTCGTTTTACAACGTCGTGACT
GGGAAAACCCTGGCGTTACCCAACTTAATCGCCTTGCAGCACATCCCCCTTTCGCCA
GCTGGCGTAATAGCGAAGAGGCCCGCACCGATCGCCCTTCCCAACAGTTGCGCAGC
CTGAATGGCGAATGGCGCGACGCGCCCTGTAGCGGCGCATTAAGCGCGGCGGGTGT
GGTGGTTACGCGCAGCGTGACCGCTACACTTGCCAGCGCCCTAGCGCCCGCTCCTTT
CGCTTTCTTCCCTTCCTTTCTCGCCACGTTCGCCGGCTTTCCCCGTCAAGCTCTAAAT
CGGGGGCTCCCTTTAGGGTTCCGATTTAGTGCTTTACGGCACCTCGACCCCAAAAAA
CTTGATTAGGGTGATGGTTCACGTAGTGGGCCATCGCCCTGATAGACGGTTTTTCGC
CCTTTGACGTTGGAGTCCACGTTCTTTAATAGTGGACTCTTGTTCCAAACTGGAACA
ACACTCAACCCTATCTCGGTCTATTCTTTTGATTTATAAGGGATTTTGCCGATTTCGG
CCTATTGGTTAAAAAATGAGCTGATTTAACAAAAATTTAACGCGAATTTTAACAAA
ATATTAACGTTTACAATTTCC 
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